var title_f12_59_13232="Chronic HSV ulcer in HIV";
var content_f12_59_13232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcer and vesicle in chronic herpes simplex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Persistent ulcer of the wrist with surrounding vesicular lesion in an HIV-infected patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt Jr, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13232=[""].join("\n");
var outline_f12_59_13232=null;
var title_f12_59_13233="Lymphoma kidney";
var content_f12_59_13233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoma affecting the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography&nbsp;of the abdomen demonstrates bulky, irregular involvement of the right kidney (red arrows), along with a moderate degree of enlargement of retroperitoneal nodes (blue arrow) in a patient with transformed follicular non-Hodgkin lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13233=[""].join("\n");
var outline_f12_59_13233=null;
var title_f12_59_13234="Construction of a colostomy - suture to abdominal wall";
var content_f12_59_13234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Construction of a colostomy - suture to abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts suturing the proximal colon limb to the dermis of&nbsp;the abdominal wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13234=[""].join("\n");
var outline_f12_59_13234=null;
var title_f12_59_13235="Calcium chloride: Patient drug information";
var content_f12_59_13235=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium chloride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=see_link\">",
"     see \"Calcium chloride: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"     see \"Calcium chloride: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect the heart from high potassium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect the heart from overdose of some heart drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691576",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect the heart and lungs from high magnesium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11304 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13235=[""].join("\n");
var outline_f12_59_13235=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855608\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014821\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014820\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014825\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014826\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014828\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014823\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014830\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=related_link\">",
"      Calcium chloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=related_link\">",
"      Calcium chloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_59_13236="Burn hand anat dig";
var content_f12_59_13236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Anatomy of a digit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 530px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13236=[""].join("\n");
var outline_f12_59_13236=null;
var title_f12_59_13237="AIDS-related Kaposis sarcoma - face";
var content_f12_59_13237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AIDS-related Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple violaceous plaques are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13237=[""].join("\n");
var outline_f12_59_13237=null;
var title_f12_59_13238="Metformin: Pediatric drug information";
var content_f12_59_13238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metformin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"    see \"Metformin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"    see \"Metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fortamet&reg;;",
"     </li>",
"     <li>",
"      Glucophage&reg;;",
"     </li>",
"     <li>",
"      Glucophage&reg; XR;",
"     </li>",
"     <li>",
"      Glumetza&reg;;",
"     </li>",
"     <li>",
"      Riomet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metformin&reg;;",
"     </li>",
"     <li>",
"      Ava-Metformin;",
"     </li>",
"     <li>",
"      CO Metformin;",
"     </li>",
"     <li>",
"      Dom-Metformin;",
"     </li>",
"     <li>",
"      Glucophage&reg;;",
"     </li>",
"     <li>",
"      Glumetza&reg;;",
"     </li>",
"     <li>",
"      Glycon;",
"     </li>",
"     <li>",
"      JAMP-Metformin;",
"     </li>",
"     <li>",
"      JAMP-Metformin Blackberry;",
"     </li>",
"     <li>",
"      Med-Metformin;",
"     </li>",
"     <li>",
"      Mylan-Metformin;",
"     </li>",
"     <li>",
"      Novo-Metformin;",
"     </li>",
"     <li>",
"      Nu-Metformin;",
"     </li>",
"     <li>",
"      PHL-Metformin;",
"     </li>",
"     <li>",
"      PMS-Metformin;",
"     </li>",
"     <li>",
"      PRO-Metformin;",
"     </li>",
"     <li>",
"      Q-Metformin;",
"     </li>",
"     <li>",
"      RAN&trade;-Metformin;",
"     </li>",
"     <li>",
"      ratio-Metformin;",
"     </li>",
"     <li>",
"      Riva-Metformin;",
"     </li>",
"     <li>",
"      Sandoz-Metformin FC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Biguanide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypoglycemic Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"      see \"Metformin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     While significant responses may not be seen at doses &lt;1500 mg daily, a lower recommended starting dose and gradual increase in dosage is recommended to minimize GI symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of type 2 diabetes mellitus (noninsulin-dependent) in previously untreated patients or patients currently receiving sulfonylurea oral antidiabetic agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 10-16 years: Initial: 500 mg twice daily; dosage increases should be made weekly, in increments of 500 mg/day in divided doses, up to a maximum of 2000 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;17 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 500 mg twice daily; dosage increases should be made weekly, in increments of 500 mg/day in 2 divided doses, up to a maximum of 2500 mg/day; doses &gt;2000 mg/day may be better tolerated divided 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Alternative dose:",
"     </b>",
"     Initial: 850 mg once daily; dosage increases should be made in increments of 850 mg every 2 weeks, given in divided doses, up to a maximum of 2550 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Glucophage&reg; XR (extended release tablets): Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2000 mg once daily. If glycemic control is not achieved at maximum dose, may divide dose to 1000 mg twice daily; if doses &gt;2000 mg/day are needed, switch to regular release tablets and titrate to maximum dose of 2550 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Glumetza&trade; (extended release tablet): Initial: 1000 mg once daily; may increase weekly as needed in 500 mg increments; not to exceed 2000 mg/day; if 2000 mg/day is ineffective, may consider using 1000 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunctive agent to diabetic patient receiving insulin: Children &ge;17 years and Adults: Initial: 500 mg metformin or metformin extended release once daily, continue current insulin dose; increase by 500 mg every week; maximum dose: 2500 mg metformin or 2000 mg metformin extended release; decrease insulin dose by 10% to 25% when fasting blood glucose &lt;120 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Metformin is contraindicated in the presence of renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Riomet&reg;: 100 mg/mL (118 mL, 473 mL) [dye free, ethanol free, sugar free; contains saccharin; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 500 mg, 850 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg;: 500 mg, 850 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg;: 1000 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortamet&reg;: 500 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg; XR: 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glumetza&reg;: 500 mg, 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucophage&reg;, Riomet&trade;: Administer in divided doses with meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucophage&reg; XR, Glumetza&trade;: Administer with evening meal; extended release tablets should be swallowed whole; do not cut, crush, or chew",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets and oral solution: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type II diabetes mellitus (noninsulin-dependent, NIDDM) as monotherapy when hyperglycemia cannot be managed with diet and exercise alone; may be used concomitantly with a sulfonylurea or insulin to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MetFORMIN may be confused with metroNIDAZOLE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Glucophage&reg; may be confused with Glucotrol&reg;, Glutofac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dianben [Spain] may be confused with Diovan brand name for valsartan [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F193913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort, flushing, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, headache, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, abdominal distention, abnormal stools, constipation, diarrhea, dyspepsia, flatulence, heartburn, indigestion, nausea, taste disorder, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Decreased vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     levels, flu-like syndrome, increased diaphoresis, nail disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Lactic acidosis, leukocytoclastic vasculitis, megaloblastic anemia, pneumonitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metformin or any component; renal disease or renal dysfunction (S",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females) or abnormal creatinine clearance which may result from clinical conditions such as cardiovascular collapse, respiratory failure, acute MI, acute CHF, and septicemia; acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving medications that may affect renal function, particularly tubular secretion, as they may also affect metformin disposition; hypoglycemia (rare with metformin) may occur with inadequate caloric intake, strenuous exercise, or concurrent use with other hypoglycemic drugs",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; withhold therapy in clinical conditions which may predispose to the development of lactic acidosis (eg, hypoxemia, dehydration, hypoperfusion, sepsis) or in any patient with CHF requiring pharmacologic management; the risk of accumulation and lactic acidosis increases with the degree of impairment of renal function and age; avoid use in patients with renal function below the limit of normal for their age;  measure baseline renal function and monitor annually; more frequent monitoring may be necessary depending upon the patient&rsquo;s clinical condition; therapy should be suspended for any surgical procedures (resume only after normal intake resumed and normal renal function is verified); temporarily discontinue therapy for 48 hours in patients undergoing radiologic studies involving the intravascular administration of iodinated contrast materials (potential for acute alteration in renal function); avoid use in patients with impaired liver function; avoid excessive acute or chronic alcohol use (alcohol potentiates the effect of metformin on lactate metabolism); lactic acidosis should be suspected in any diabetic patient receiving metformin who has evidence of acidosis when evidence of ketoacidosis is lacking",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1060256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the extent and slightly delays the absorption (clinical significance unknown); may decrease absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folic acid",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal studies; therefore, metformin is classified as pregnancy category B. Metformin has been found to cross the placenta in concentrations which may be comparable to those found in the maternal plasma. Pharmacokinetic studies suggest that clearance of metformin may be increased during pregnancy and dosing may need adjusted in some women when used during the third trimester.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fetal, neonatal, and maternal outcomes have been evaluated following maternal use of metformin for the treatment of GDM and type 2 diabetes. Available information suggests that metformin use during pregnancy may be safe as long as good glycemic control is maintained; however, many studies used metformin during the second or third trimester only. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metformin has also been evaluated for the treatment of PCOS, a syndrome which may exhibit oligomenorrhea and, in some women, hyperinsulinemia. It is not recommended as first-line therapy; when used to treat infertility related to PCOS, current guidelines restrict the use of metformin to women with glucose intolerance. Because ovulation rates will likely improve in women with PCOS who are taking metformin, appropriate contraceptive measures should be discussed in women who are not attempting to conceive.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fasting blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     , initial and periodic monitoring of hemoglobin, hematocrit, and red blood cell indices; renal function (baseline and annually)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1060247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Target range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Blood glucose: Fasting and preprandial: 80-120 mg/dL; bedtime: 100-140 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glycosylated hemoglobin (hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ): &lt;7%",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity (increases peripheral glucose uptake and utilization)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within days, maximum effects up to 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Average decrease in fasting blood glucose: Children &gt;10 years and Adults: 60-70 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Slowly and incompletely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 654 &plusmn; 358 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 50% to 60% (under fasting conditions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, plasma elimination: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release formulation: 2-4 hours; extended release formulation: 4-8 hours (median: 7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal; tubular secretion is major route; excretion: 90% in urine as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Removed by hemodialysis; clearance up to 170 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"      see \"Metformin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not change dose or discontinue without consulting prescriber; avoid alcohol while taking this medication, could cause severe reaction; maintain regular dietary intake and exercise routine; always carry quick source of sugar with you; during the first weeks of therapy, side effects such as headache, nausea, vomiting, or diarrhea may occur; consult prescriber if these persist; report severe or persistent side effects, extended vomiting or flu-like symptoms, skin rash, easy bruising or bleeding, or change in color of urine or stool; contact your healthcare provider immediately if you feel very weak, tired, or uncomfortable, have unusual muscle pain, trouble breathing, unusual stomach discomfort, are dizzy or lightheaded, or suddenly develop a slow or irregular heartbeat; parts of the extended release tablet (which do not contain active ingredient) may be found excreted in the stool",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1060254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When transferring therapy from chlorpropamide to metformin, monitor the patient closely during the first 2 weeks due to the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia; if the patient has not responded to 4 weeks at the maximum metformin dosage, consider a gradual addition of a sulfonylurea antidiabetic agent, even if prior primary or secondary failure to a sulfonylurea has occurred; continue metformin at the maximum dose",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/59/13238/abstract-text/10454950 /pubmed\" id=\"10454950 \" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones K, Arlanian S, McVie R, et al, &ldquo;Metformin Improves Glycemic Control in Children With Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 2000, 49(Suppl 1):A75.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Type 2 Diabetes in Children and Adolescents. American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(3):381-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/59/13238/abstract-text/ 10868870 /pubmed\" id=\" 10868870 \" target=\"_blank\">",
"        10868870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12589 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13238=[""].join("\n");
var outline_f12_59_13238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709034\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193858\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193859\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060245\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060238\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193832\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193817\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060249\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060241\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060248\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193915\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193913\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060253\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060237\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060236\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299680\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193826\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060256\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193828\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193843\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060244\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060247\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060235\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060251\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060252\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060243\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060254\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12589|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=related_link\">",
"      Metformin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=related_link\">",
"      Metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_59_13239="Hymenoptera venom immunotherapy: Determining duration of therapy";
var content_f12_59_13239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hymenoptera venom immunotherapy: Determining duration of therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13239/contributors\">",
"     Ulrich R Muller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13239/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13239/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/59/13239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom immunotherapy (VIT) is highly effective for the treatment of patients with systemic allergic reactions to Hymenoptera venom. More than 95 percent of patients allergic to vespid (ie, yellow jacket, hornet, and wasp) venom, and 80 to 90 percent of those allergic to honey bee venom will not develop any systemic allergic symptoms if re-stung while receiving VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The rest usually experience only mild symptoms.",
"   </p>",
"   <p>",
"    After the introduction of VIT in the 1970s, it was initially believed that therapy would need to be continued indefinitely in most patients. However, reports began to appear describing relatively good outcomes in patients who chose to stop their venom injections for various reasons. In addition, a subset of patients on VIT showed skin test or serologic evidence of loss of sensitivity, ie, skin tests to venom converted to negative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum levels of venom-specific IgE antibodies fell to low levels. Finally, the cost and inconvenience of life-long injections are not insignificant. For these reasons, a number of studies were initiated from the mid 1980s to try to determine if and when VIT could be safely stopped.",
"   </p>",
"   <p>",
"    This topic will review the studies that have addressed this question and discuss the risk factors for recurrent systemic reactions to Hymenoptera stings after the discontinuation of VIT. The efficacy, indications, and other issues concerning VIT are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a recurrent systemic reaction to a sting after stopping VIT decreases the longer VIT has lasted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/8\">",
"     8",
"    </a>",
"    ]. After three to five years of VIT, most patients will be protected from recurrent systemic allergic reactions (SARs), and this is the suggested minimum duration of therapy. This recommendation is based upon the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One year of treatment &mdash; An early retrospective study evaluated recurrent systemic reactions to stings in 82 patients who chose to stop VIT after varying amounts of time, with a mean duration of treatment of 14 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/9\">",
"       9",
"      </a>",
"      ]. Over the ensuing three to four years, 22 percent of those who were re-stung had SARs, compared to 1 to 3 percent of patients who remained on VIT. Thus, one year of VIT did not provide sufficient protection for nearly one-quarter of patients.",
"     </li>",
"     <li>",
"      At least three years of treatment &mdash; Several prospective studies evaluated the protection afforded by VIT if it was given for at least three years and then stopped (",
"      <a class=\"graphic graphic_table graphicRef72537 \" href=\"UTD.htm?43/12/44236\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10-16\">",
"       10-16",
"      </a>",
"      ]. Most of the patients in these early studies were selected because they showed evidence of a reduction in sensitivity to venom in response to VIT, either through skin tests or serum tests, so their prognosis may have been better as a group. After three years of VIT, 83 to 100 percent of patients remained protected against recurrent SARs in the first one to three years after stopping. Most or all of the patients who did develop SARs with repeat stings after stopping VIT had only mild symptoms.",
"     </li>",
"     <li>",
"      At least five years of treatment &mdash; Studies of &ge;5 years of treatment show slightly higher rates of protection, even in unselected groups of patients. In one study, the percentage of patients who developed SARs after stopping VIT was significantly lower (5 percent) among patients who had received VIT for &ge;50 months, compared with 18 percent among those who received treatment for 33 to 49 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10\">",
"       10",
"      </a>",
"      ]. Another study evaluated 74 patients treated with VIT for at least five years, who volunteered to stop treatment and undergo periodic testing and sting challenges every one to two years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/17\">",
"       17",
"      </a>",
"      ]. Over the ensuing two to five years, systemic symptoms occurred in",
"      <span class=\"nowrap\">",
"       7/74",
"      </span>",
"      patients (10 percent), or in",
"      <span class=\"nowrap\">",
"       8/270",
"      </span>",
"      challenges (3 percent), and just two reactions required epinephrine injection. In a second study of 29 adults with vespid venom allergy, there were no recurrent SARs upon challenge one year after stopping treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, three years of VIT protects the majority of patients, although the studies showing this disproportionately included patients with good prognoses. Extending treatment to five years protects the majority of unselected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR RECURRENT SARS OR POOR OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of patient-specific risk factors for the recurrence of a systemic allergic reaction (SAR) to Hymenoptera stings following VIT were identified by analyzing the studies reviewed above (",
"    <a class=\"graphic graphic_table graphicRef66059 \" href=\"UTD.htm?30/56/31627\">",
"     table 2",
"    </a>",
"    ). Other characteristics, such as sex or the presence of atopic disorders, do not influence the risk of a relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Older age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children have a lower risk for recurrent SARs than adults after discontinuing VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In a representative study, SARs were reported in 8.3 percent of children, compared to 13.1 percent of adults who were stung within seven years after stopping VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10\">",
"     10",
"    </a>",
"    ]. Another study reported that only 5 percent of children (with initial moderate to severe reactions) experienced recurrent SARs when evaluated more than 10 years after stopping VIT, compared with a rate of 16 percent in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe pretreatment reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe initial sting reactions are at higher risk for a recurrent SAR both during and after completion of VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/20\">",
"     20",
"    </a>",
"    ]. Combining the data from four prospective studies involving 386 patients, relapses were observed in 4 percent of those with mild initial reactions, compared with 14 percent of those with severe pretreatment reactions (",
"    <a class=\"graphic graphic_table graphicRef51249 \" href=\"UTD.htm?30/45/31452\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10,17,21,22\">",
"     10,17,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bee venom allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bee venom allergy are at higher risk for recurrent SARs than those allergic to vespid venoms, both before and after VIT. Before treatment, 51 percent of bee-allergic patients develop recurrent SARs upon sting challenge, compared with 25 percent of those allergic to vespid venoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During and after VIT, patients allergic to bee venom remain at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. In one study of VIT of three years duration, the relapse rate in patients allergic to bee venom was 16 percent, compared with 8 percent of patients allergic to vespid venoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for this difference are not entirely clear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The venom content of a honey bee sting is much higher than that of a vespid sting. It is also possible that vespid stings are more variable in venom content than bee stings, because vespids retain their stingers after stinging, and thus insects can sting more than once, while honey bees lose their sting apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9271?source=see_link\">",
"     \"Bees, yellow jackets, hornets, and wasps: Biology and identification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with concomitant cardiovascular disease are at increased risk for severe systemic allergic reactions to Hymenoptera stings and poor outcomes resulting from stings, including myocardial and cerebrovascular infarction, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/25\">",
"     25",
"    </a>",
"    ]. This is probably also true for patients with chronic pulmonary diseases, such as COPD or asthma, although it is less well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reactions to injections or stings during VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop general allergic reactions to VIT injections or to repeat stings during VIT are at higher risk for reactions after VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. In one study, those who had systemic reactions to injections during treatment had a 38 percent chance of relapse, compared with a 7 percent chance among those who tolerated injections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have recurrent SARs during maintenance VIT should be evaluated for mast cell disorders with a baseline serum tryptase level. In addition, a higher maintenance dose of venom is recommended to achieve protection in such individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/26\">",
"     26",
"    </a>",
"    ]. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H25#H25\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Treatment failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extreme sensitivity on diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have reported an association between recurrent SARs after stopping VIT and persistent high sensitivity on diagnostic tests for venom sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/19\">",
"     19",
"    </a>",
"    ]. However, others have not been able to confirm this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'The role of testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mast cell disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mast cell disorders can experience severe anaphylaxis with Hymenoptera stings. Most of these patients have skin test or serologic evidence of venom allergy, although some do not [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Conversely, a significant percentage of patients with severe shock reactions following Hymenoptera stings have evidence of a mast cell disorder. Up to one-third of patients with severe anaphylactic reactions from stings demonstrate an elevated baseline serum tryptase level (ie, &gt;11.4",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    whereas an elevated serum tryptase level is observed in less than 5 percent of an unselected adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mast cell disorders, including an elevated baseline serum tryptase, and venom allergy can be successfully treated with VIT, and they appear to be at high-risk for recurrent SARs if treatment is discontinued. Two female patients with urticaria pigmentosa and vespid allergy died from stings sustained three and nine years after stopping VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/34\">",
"     34",
"    </a>",
"    ]. Based on such reports, it has been recommended that patients with mastocytosis and Hymenoptera venom allergy receive life-long VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/35\">",
"     35",
"    </a>",
"    ]. These patients must also understand that they remain at elevated risk despite treatment and must carry at least one epinephrine autoinjector at all times [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/26\">",
"     26",
"    </a>",
"    ]. The management of venom allergy in patients with systemic mastocytosis is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of systemic mastocytosis\", section on 'Venom immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Time since stopping therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be some loss of effect over time after patients stop VIT, although most remain sufficiently protected. Those who experience SARs generally (but not always) have mild symptoms. Protection up to seven years after discontinuing VIT was analyzed in four studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10,17,19,21,22\">",
"     10,17,19,21,22",
"    </a>",
"    ]. These studies reported complete protection in 80 to 91 percent of patients, a slightly lower percentage than in studies of the first three years off therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Duration of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Repeated stings after stopping VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are stung repeatedly after stopping VIT have a greater chance of eventually having a recurrent systemic reaction compared to those who are stung infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. The severity of SARs tends to increase in response to repeated stings in patients who have discontinued VIT. In one study of 200 patients treated with at least three years of VIT, 25 patients were re-stung and 84 percent of them experienced no reaction or only a mild SAR to the initial posttreatment sting (",
"    <a class=\"graphic graphic_table graphicRef76805 \" href=\"UTD.htm?33/5/33883\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10\">",
"     10",
"    </a>",
"    ]. Additional stings occurred in 17, and these were moderate to severe in 53 percent (",
"    <a class=\"graphic graphic_table graphicRef76805 \" href=\"UTD.htm?33/5/33883\">",
"     table 4",
"    </a>",
"    ). Another study reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/36\">",
"     36",
"    </a>",
"    ]. Therefore, patients should continue their efforts to avoid being stung after stopping VIT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/22/6502?source=see_link\">",
"     \"Bees, yellow jackets, hornets, and wasps: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DECIDING TO STOP THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to continue or stop VIT is usually raised after the patient has received at least three and preferably five years of maintenance injections, as discussed previously (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Duration of treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The decision to stop VIT can be relatively complex and experts may approach it differently. The allergy specialist should consider the patient's sensitivity according to repeat diagnostic testing, together with other individual risk factors, including relevant comorbid conditions and vocational and recreational activities. The patient's comfort with risk and other preferences must also be factored into the decision. No two situations are identical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Candidates for indefinite therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent SARs among patients who continue VIT indefinitely is believed to remain low. Life-long VIT should be considered for patients with any of the risk factors for recurrent SARs discussed above. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life-threatening initial SARs and a high likelihood of recurrent stings in the future due to occupational or recreational activities.",
"     </li>",
"     <li>",
"      Honey bee allergy and a high likelihood of recurrent stings in the future (eg, bee keepers and their family members).",
"     </li>",
"     <li>",
"      Significant cardiovascular disease.",
"     </li>",
"     <li>",
"      Recurrent SARs to VIT injections, or recurrent SARs to re-stings during maintenance VIT. The management of recurrent SARs to VIT injections is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H16#H16\">",
"       \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Systemic reactions to VIT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anxiety concerning the residual risk of a repeat reaction.",
"     </li>",
"     <li>",
"      Requirement for higher venom doses to achieve adequate protection.",
"     </li>",
"     <li>",
"      Mast cell disorders or an elevated baseline level of serum tryptase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     The role of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests are generally repeated when considering discontinuation of VIT, even though none of these tests predicts an individual patient's risk of recurrent SARs. However, the information they provide allows the allergy specialist to assess whether the patient has responded as anticipated to treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Venom-specific serum IgE values usually rise during the first months of venom immunotherapy and then fall during the following three to five years of VIT, to levels below the pretreatment value. However, these changes are not reliably predictive of protection for recurrent SARs.",
"     </li>",
"     <li>",
"      Venom-specific IgG levels usually rise and remain elevated, but do not correlate closely with protection, especially after several years of treatment.",
"     </li>",
"     <li>",
"      A reduction in reactivity on skin testing is seen in most patients, but is not predictive by itself.",
"     </li>",
"     <li>",
"      Persistent high sensitivity on diagnostic tests (either skin or in vitro tests) may be a risk factor for recurrent SARs after stopping VIT. Therefore, continuation of VIT until diagnostic tests show a clear decrease in sensitivity has been recommended in this situation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of a NEGATIVE intradermal skin test at a venom concentration of 1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and the ABSENCE of venom specific serum IgE-antibodies (ie, &lt;0.35",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      in most laboratories) is associated with a strongly diminished risk of relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/10,12,21\">",
"       10,12,21",
"      </a>",
"      ]. However, only about 25 percent of patients become skin test negative after five to six years of VIT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13239/abstract/16,17\">",
"       16,17",
"      </a>",
"      ] and an even smaller group achieves both negative skin tests and in vitro tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, if a patient has significant risk factors for recurrent SARs and indications for indefinite VIT, then repeat testing is",
"    <strong>",
"     NOT",
"    </strong>",
"    necessary, since the results will not change the decision to continue VIT. It is our practice to repeat testing only in those patients in whom we are considering stopping VIT after three to five years. In this setting, we usually perform skin testing and measure venom-specific IgE antibodies, to assess how these parameters have changed compared to the pretreatment results.",
"   </p>",
"   <p>",
"    The decision to stop VIT is sometimes straightforward. For example, most allergists would readily discontinue treatment in the individual with a history of moderate SARs to stings, in whom both skin tests and venom-specific IgE have become negative after three years of VIT. However, if the same patient had a persistently high level of serum-specific IgE after five years of VIT and was a farmer or gardener, the decision becomes far more difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COUNSELING THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The allergy specialist should ensure that patients who discontinue VIT understand the following about their risk for a recurrent SAR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of a recurrent serious reaction is not zero, and may be as high as 10 percent per sting.",
"     </li>",
"     <li>",
"      Because of the residual risk, the patient should continue to carry an epinephrine autoinjector and take measures to avoid Hymenoptera.",
"     </li>",
"     <li>",
"      It is possible to react to one sting and not another, so an uneventful sting does not mean the patient is \"cured\" of their allergy.",
"     </li>",
"     <li>",
"      Any serious SARs should be reported to the allergy specialist so that the patient's situation can be re-evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Venom immunotherapy (VIT) is highly effective and reduces a patient's risk of a recurrent systemic allergic reaction (SAR) to less than 10 percent in most patients while they continue to receive maintenance injections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of a recurrent SAR to a sting decreases the longer VIT is continued. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for recurrent SARs after stopping VIT and for a poor outcome as a result of a sting have been identified. (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for recurrent SARs or poor outcomes'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients",
"      <strong>",
"       without any",
"      </strong>",
"      of the identified risk factors, we suggest continuing VIT for five rather than three years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients",
"      <strong>",
"       with",
"      </strong>",
"      <strong>",
"       one or more",
"      </strong>",
"      of the identified risk factors, we suggest continuing VIT indefinitely (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Candidates for indefinite therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When considering the discontinuation of VIT for a specific patient, we perform a repeat venom skin test and measure venom-specific IgE serum antibodies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Deciding to stop therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'The role of testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We advise patients who stop VIT to carry an epinephrine autoinjector indefinitely and continue measures to avoid Hymenoptera. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Counseling the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/1\">",
"      Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/2\">",
"      M&uuml;ller U, Thurnheer U, Patrizzi R, et al. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979; 34:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/3\">",
"      Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/4\">",
"      M&uuml;ller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/5\">",
"      Ru&euml;ff F, Przybilla B, M&uuml;ller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy 1996; 51:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/6\">",
"      Bonifazi F, Jutel M, Bil&oacute; BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/7\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/8\">",
"      Golden DB. Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol 2010; 10:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/9\">",
"      Golden DB, Johnson K, Addison BI, et al. Clinical and immunologic observations in patients who stop venom immunotherapy. J Allergy Clin Immunol 1986; 77:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/10\">",
"      Lerch E, M&uuml;ller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/11\">",
"      Urbanek R, Forster J, Kuhn W, Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 1985; 107:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/12\">",
"      M&uuml;ller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/13\">",
"      Haugaard L, N&oslash;rregaard OF, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/14\">",
"      Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/15\">",
"      van Halteren HK, van der Linden PW, Burgers JA, Bartelink AK. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997; 100:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/16\">",
"      Golden DB, Addison BI, Gadde J, et al. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989; 84:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/17\">",
"      Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/18\">",
"      Golden DB, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/19\">",
"      Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000; 105:385.",
"     </a>",
"    </li>",
"    <li>",
"     M&uuml;ller U. Insect sting allergy: Clinical picture, diagnosis and treatment, Gustav/Fischer, Stuttgart; New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/21\">",
"      Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/22\">",
"      Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998; 101:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/23\">",
"      Blaauw PJ, Smithuis LO. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting. J Allergy Clin Immunol 1985; 75:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/24\">",
"      van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994; 94:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/25\">",
"      Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/26\">",
"      Ru&euml;ff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/27\">",
"      M&uuml;ller UR, Horat W, W&uuml;thrich B, et al. Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol 1983; 72:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/28\">",
"      Fricker M, Helbling A, Schwartz L, M&uuml;ller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/29\">",
"      Wagner N, Fritze D, Przybilla B, et al. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol 2008; 146:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/30\">",
"      Reimers A, M&uuml;ller U. Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. J WAO Org 2005; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/31\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/32\">",
"      Ludolph-Hauser D, Ru&euml;ff F, Fries C, et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/33\">",
"      Haeberli G, Br&ouml;nnimann M, Hunziker T, M&uuml;ller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/34\">",
"      Oude Elberink JN, de Monchy JG, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/35\">",
"      Bonadonna P, Zanotti R, M&uuml;ller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010; 10:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13239/abstract/36\">",
"      Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008; 100:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4089 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13239=[""].join("\n");
var outline_f12_59_13239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR RECURRENT SARS OR POOR OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Older age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe pretreatment reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bee venom allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reactions to injections or stings during VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extreme sensitivity on diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Time since stopping therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Repeated stings after stopping VIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DECIDING TO STOP THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Candidates for indefinite therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      The role of testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COUNSELING THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4089\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4089|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/12/44236\" title=\"table 1\">",
"      Protection 1 to 5 years after stopping VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/56/31627\" title=\"table 2\">",
"      Risk of recurrent systemic reaction after VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/45/31452\" title=\"table 3\">",
"      Initial reaction severity vs risk after VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/5/33883\" title=\"table 4\">",
"      Anaphylaxis severity with multiple stings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/22/6502?source=related_link\">",
"      Bees, yellow jackets, hornets, and wasps: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9271?source=related_link\">",
"      Bees, yellow jackets, hornets, and wasps: Biology and identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_59_13240="Transesophageal echocardiography in the evaluation of the left ventricle";
var content_f12_59_13240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transesophageal echocardiography in the evaluation of the left ventricle",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13240/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13240/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13240/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/59/13240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although transthoracic echocardiography remains the cornerstone of diagnostic cardiac ultrasound, transesophageal echocardiography (TEE) is a valuable complementary tool. As compared with transthoracic echocardiography, TEE offers superior visualization of posterior cardiac structures because of close proximity of the esophagus to the posteromedial heart with lack of intervening lung and bone. This proximity permits use of high-frequency imaging transducers that afford superior spatial resolution (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69251 \" href=\"UTD.htm?16/4/16463\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    TEE displays most of the left ventricle (LV) with definition that is equal or superior to that achieved with transthoracic echocardiography. In particular, the full thickness of the myocardium, including the endocardium with its complex endo-architecture, is seen with clarity. However, most TEE views do not fully display the apical portion of the LV, which is truncated or foreshortened. This shortcoming lowers the sensitivity of TEE for detecting a wall motion abnormality limited to the apex, leads to underestimation of chamber volume, and may result in misinterpretation of global LV systolic function. Importantly, the presence of apical thrombus may be missed on TEE alone.",
"   </p>",
"   <p>",
"    The use of TEE for the evaluation of the LV will be reviewed here. The specific roles for TEE in ischemic heart disease, valvular disease, and aortic pathology are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31878?source=see_link\">",
"     \"Transesophageal echocardiography in traumatic rupture of the aortic isthmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTOLIC FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While quantitative methods to measure LV systolic function and ejection fraction by TEE have been described, most evaluation of the LV is qualitative. Studies by anesthesiologists in the operating room have documented the validity of this approach for recognizing hypovolemia, the adverse effects of proximal cross-clamping of the aorta, and the influence of various anesthetic regimens on LV systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. When evaluating left ventricular function, it is important to take the patient's overall condition into consideration. Volume status, sedating medications, and general anesthesia may alter both systolic and diastolic function through their effects on preload and afterload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ejection fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of end-diastolic and end-systolic volumes by TEE using the biplane method of discs (ie, Simpson's rule) systematically underestimates LV size [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A non-volumetric method has been described that accurately estimates LV ejection fraction using the descent of the mitral annulus toward the apex as an index of the shortening of the ventricular long axis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of LV function (global and segmental) should also include a transgastric short-axis view. Although this view must be used with some degree of caution because it excludes the longitudinal motion of the heart (ie, basal descent), it remains a reliable approach for judging LV systolic function. With multiplane and three-dimensional TEE, this view can be supplemented with long-axis gastric views that approach the LV apex in some patients, and reliably image the basal inferior wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fractional area change",
"    </span>",
"    &nbsp;&mdash;&nbsp;In lieu of LV ejection fraction, the fractional area change or area ejection fraction (normal &gt;36 percent) has been used, mainly for research purposes, for quantifying changes in the short-axis image of the LV. Using manual planimetry of the area circumscribed by the endocardium at end-diastole (EDA) and end-systole (ESA), the fractional area change can be calculated according to the formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Fractional area change = (EDA - ESA) &divide; EDA",
"   </p>",
"   <p>",
"    The validity of utilizing the fractional area change was evaluated in one study that compared radionuclide blood pool imaging to TEE area ejection fraction in a group of 10 patients in the postsurgical intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/10\">",
"     10",
"    </a>",
"    ]. With LV ejection fractions below 45 percent, the correlation between the reference standard blood pool image and the short-axis measured by planimetry was linear; the correlation was poorer when ejection fractions were normal or above normal. However, discriminating among high ejection fractions is of minor clinical importance, and, as a result, use of the fractional short-axis area change can be considered a valid approach. Fractional area change has also been corrected for afterload using the following formula [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/11\">",
"     11",
"    </a>",
"    ] :",
"   </p>",
"   <p>",
"    FAC afterload corrected (FACac) = FAC x",
"    <span class=\"nowrap\">",
"     log",
"     <sub>",
"      10",
"     </sub>",
"     ([MAP-RAP]/CI)",
"    </span>",
"    x 100%",
"   </p>",
"   <p>",
"    Studies applying this method in comparison with pressure-volume loops intraoperatively have validated this method as being relatively independent of loading conditions.",
"   </p>",
"   <p>",
"    In addition, if one considers that the descent of the cardiac base represents longitudinal muscle function and is among the first properties to be altered in patients with systolic dysfunction, it is to be expected that an index that is blind to longitudinal changes in cardiac dimensions would be less effective once that vector of motion had been suppressed. The reproducibility of measuring the area and fractional change of the short-axis appears to be acceptable for clinical and investigational use [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1034768788\">",
"    <span class=\"h2\">",
"     Strain analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two clinically applicable methods for measuring myocardial deformation and deriving indices of systolic function are tissue Doppler and speckle tracking. These methods have now been applied to transesophageal imaging. Available studies have primarily been performed in the intraoperative setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study, tissue Doppler in 19 intraoperative patients was successful in measuring radial strain and strain rate in the transgastric views in contrast to the speckle-tracking method, which was less successful. However, a second study demonstrated that speckle tracking measurements of radial and longitudinal strain were more successful at differentiating between perfused and non-perfused myocardial segments when compared with visual estimation of wall motion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/15\">",
"     15",
"    </a>",
"    ]. Normal values for global strain rate have not been established by transesophageal echocardiography. Normal values for global longitudinal strain using various techniques applied to transthoracic echocardiography range between -16 and -19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Normal radial strain values are between 45 and 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link\">",
"     \"Tissue Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler evaluation of LV systolic performance is also feasible. Cardiac output has been measured from the pulmonary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] and LV outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/21\">",
"     21",
"    </a>",
"    ] with the use of velocity-time integrals obtained by pulsed-wave Doppler and continuous-wave Doppler [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/22\">",
"     22",
"    </a>",
"    ] combined with outflow tract diameter estimates of area. Other flow signals, such as transmitral inflow, may also provide cardiac output information. Tissue Doppler measurements of peak systolic myocardial velocity using the basal lateral wall were validated as a measure of systolic LV function against intraoperative pressure-volume loops [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/23\">",
"     23",
"    </a>",
"    ]. Unlike",
"    <span class=\"nowrap\">",
"     dP/dt",
"    </span>",
"    derived from the mitral regurgitant jet, the peak systolic myocardial velocity was relatively independent of loading conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6508067\">",
"    <span class=\"h2\">",
"     Evaluation of regional wall motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in wall motion associated with myocardial ischemia or infarction are characterized by diminished or absent inward endocardial motion and by impaired systolic myocardial thickening. TEE is sensitive for the detection of acute ischemia or prior infarction and is therefore useful for assessment of regional wall motion as well as global left ventricular function.",
"   </p>",
"   <p>",
"    As an example, the continuous high-quality imaging of the left ventricle afforded by TEE during surgical procedures makes it ideally suited for the early detection of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Intraoperative changes in wall motion are more predictive of postoperative ischemia or infarction than ECG changes or hemodynamic abnormalities as documented with Swan-Ganz catheter measurements, such as an increase in pulmonary capillary wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ]. In a study of 98 patients studied before and after the induction of anesthesia prior to coronary artery bypass graft surgery, ischemia as defined by TEE was associated with a small elevation in PCWP (3.5 mmHg); however, a rise in PCWP itself had a low sensitivity and predictive value for myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6508074\">",
"    <span class=\"h3\">",
"     Views used for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transverse and longitudinal plane transgastric views are the most widely used for evaluating wall motion abnormalities. The standard transesophageal left ventricular short axis view (horizontal plane) is obtained at the level of the papillary muscle tips. At this level, the myocardium is supplied by all three major coronary vessels and can be divided into four or six segments for standardization purposes: anterior, anterolateral, inferolateral, inferior, inferoseptal, and anteroseptal (",
"    <a class=\"graphic graphic_figure graphicRef55855 graphicRef62482 \" href=\"UTD.htm?9/5/9301\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Continuous imaging of this cross-sectional view forms the basis of monitoring wall motion before and immediately after coronary artery bypass surgery and in high-risk patients undergoing non-cardiac surgery. The longitudinal transgastric view, as well as the esophageal views, provide incremental value in detecting additional ischemic segments [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6508081\">",
"    <span class=\"h3\">",
"     Measurement of wall motion abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely employed method for measuring segmental wall motion uses qualitative analysis of endocardial wall motion and segmental thickening (",
"    <a class=\"graphic graphic_figure graphicRef55855 graphicRef62482 \" href=\"UTD.htm?9/5/9301\">",
"     figure 1A-B",
"    </a>",
"    ). By convention, segment systolic wall thickening and endocardial inward motion are usually graded as [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal",
"     </li>",
"     <li>",
"      Hypokinetic (ie, reduced and delayed contraction)",
"     </li>",
"     <li>",
"      Akinetic (ie, absence of inward motion and thickening)",
"     </li>",
"     <li>",
"      Dyskinetic (ie, systolic thinning and outward systolic endocardial motion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Akinesia and dyskinesia usually are the result of a prior myocardial infarction and therefore often reflect nonviable myocardium. Hypokinetic segments, which may result purely from ischemia but may also reflect a prior non-transmural myocardial infarction, generally have at least some viability and often reflect hibernating myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6508088\">",
"     'Limitations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6508088\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some potential limitations to utilizing TEE for the assessment of regional wall motion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with conduction abnormalities, such as left bundle branch block, or ventricular pacing, it can be difficult to distinguish the incoordinate contractions resulting from delayed activation from those of an ischemic wall motion abnormality.",
"     </li>",
"     <li>",
"      Regional wall motion abnormalities are not exclusive to ischemia, since they can also be seen with a nonischemic cardiomyopathy. In addition, myocardial stunning may explain a wall motion abnormality in an adequately revascularized region. It may be difficult to differentiate this finding from ischemia due to inadequate revascularization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"       \"Clinical syndromes of stunned or hibernating myocardium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other possible influences that confound the recognition of acute ischemia by TEE include volume changes and alterations in transducer position",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angulation, which create de novo unmasking of pre-existing wall motion abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIASTOLIC FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastole includes a period of active relaxation during isovolumic relaxation and rapid early filling, a period of passive filling during diastasis, and active filling during atrial contraction. The first phase of early relaxation is energy dependent, the second phase of passive filling is dependent upon ventricular compliance, and the third phase during atrial contraction is highly dependent upon the LV diastolic pressure at the onset of atrial contraction. Impaired LV relaxation, poor LV compliance, or both may be the pathophysiologic mechanisms leading to pulmonary congestion and clinical symptoms of heart failure in patients with diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/32\">",
"     32",
"    </a>",
"    ]. The rates of relaxation and the filling characteristics are dependent upon preload, afterload, heart rate, and contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mitral inflow filling pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral inflow, alone and in combination with pulmonary venous flow, is the major source of clinically relevant information about diastolic LV behavior. As with transthoracic echocardiography, transmitral inflow is recorded with the Doppler sample volume at the tips of the mitral leaflets from the esophageal view plane that provides the most axial inflow signal (",
"    <a class=\"graphic graphic_waveform graphicRef65233 graphicRef59321 \" href=\"UTD.htm?8/58/9127\">",
"     waveform 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H3#H3\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Doppler mitral inflow velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important diagnostic parameters derived from the mitral inflow signals include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The ratio of peak early filling velocity to atrial filling velocity (E to A ratio)",
"     </li>",
"     <li>",
"      The deceleration time of early filling curve",
"     </li>",
"     <li>",
"      The isovolumic relaxation time",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two predominant patterns of flow have been recognized on the TEE, reflecting the two major categories of diastolic dysfunction. These are the same as has been seen on transthoracic echocardiography (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An impairment in LV relaxation or delayed relaxation is characterized by a decrease in the transmitral E to A ratio (the so-called A-wave dominant pattern), which arises through a combination of prolonged deceleration time and increased contribution of atrial contraction. This form of diastolic dysfunction occurs in LV hypertrophy of any cause and with normal aging. The delayed relaxation inflow pattern usually implies a normal mean filling pressure.",
"     </li>",
"     <li>",
"      Diminished or impaired LV filling with elevated diastolic filling pressure is identified by Doppler by \"restrictive flow\" pattern, with an increased transmitral E to A ratio, a shortened isovolumic relaxation time, and a short deceleration time. This pattern occurs in patients with restrictive cardiomyopathies, such as amyloid heart disease, and in patients with acute and chronic cardiac decompensation associated with a variety of myopathic and pericardial conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As heart failure worsens, a pattern change from delayed relaxation to restriction is often seen. At one point in this progression, as filling pressure rises to pathologic levels, the filling pattern will \"pseudonormalize\" (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In evaluating diastolic function by TEE it is always important to recognize that Doppler transmitral filling patterns are influenced by a variety of factors, including loading conditions, heart rate, pericardial restraint, left atrial pressure and compliance, right and left ventricular interaction, coronary turgor, and intrinsic properties of left atrial and LV muscle. As an example, changes in loading conditions during cardiac surgery may induce several changes in filling patterns over the course of a single operation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary venous Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deducing the status of diastolic function through evaluating transmitral inflow patterns is greatly enhanced by also examining the Doppler signals from the pulmonary veins. These signals are particularly accessible and well-resolved when sampled with the aid of",
"    <span class=\"nowrap\">",
"     TEE/Doppler.",
"    </span>",
"    Signals obtained in this manner have contributed substantially to our understanding of diastolic hemodynamics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H4#H4\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Pulmonary venous flow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TEE demonstrates the entrance of the four pulmonary veins into the left atrium. In the transverse view, the left upper pulmonary vein flow is close to and parallel to the direction of the interrogating beam, and highly resolved color flow Doppler images are readily obtained, helping to guide positioning of the pulsed-wave Doppler sample volume into the proximal 1 cm of the vein. The right upper pulmonary vein is close to and parallel to the direction of the interrogating beam when observed at the vertical (90 degree) view.",
"   </p>",
"   <p>",
"    Flow in the pulmonary veins is triphasic (",
"    <a class=\"graphic graphic_figure graphicRef68801 graphicRef87117 \" href=\"UTD.htm?14/25/14744\">",
"     figure 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62749 graphicRef77774 \" href=\"UTD.htm?40/62/41958\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The systolic phase is predominant, accounting for more than 55 percent of the total flow integral. The systolic phase consists of two components. The first component results from active atrial relaxation and the second from systolic descent of the cardiac base [",
"      <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second phase occurs in early diastole and accounts for approximately 40 percent of the total forward inflow. This phase results from ventricular relaxation.",
"     </li>",
"     <li>",
"      The third phase occurs in late diastole and is due to atrial contraction. The atrial phase is retrograde and usually small.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Frequently measured variables from pulmonary venous flow velocity tracings with demonstrated utility include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peak systolic and peak early diastolic flow velocities",
"     </li>",
"     <li>",
"      Peak velocities of flow reversal at atrial contraction",
"     </li>",
"     <li>",
"      Velocity-time integrals of the systolic, early diastolic, and atrial contraction phases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The systolic velocity-time integral (S) is measured from the onset of forward flow following the peak R wave on the electrocardiogram to the point at which it reaches zero flow velocity. The early diastolic velocity-time integral (D) is measured from the onset of the second wave to its crossover with the zero-line. The systolic fraction is equal to",
"    <span class=\"nowrap\">",
"     S/(S",
"    </span>",
"    + D). The velocity-time integral of the late diastolic A wave (retrograde flow during atrial contraction) is measured from its onset to the end of negative flow.",
"   </p>",
"   <p>",
"    In conditions that elevate LV filling patterns, systolic dominance of inflow ceases and its contribution (measured from its VTI) becomes less than 50 percent of total inflow. Concurrently, retrograde atrial flow may increase and its duration exceeds forward atrial transmitral valve [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/41\">",
"     41",
"    </a>",
"    ]. However, in a study of 102 patients, there was poor correlation between the systolic fraction of pulmonary venous flow, the mitral",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio, and the pulmonary capillary wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/42\">",
"     42",
"    </a>",
"    ]. In a regression analysis, the limits of agreement exceeded 10 mmHg, rendering this method unreliable for estimating filling pressures intraoperatively. Additionally, there are numerous other conditions that impact pulmonary venous flow patterns including atrial fibrillation and severe mitral regurgitation, in which systolic flow reversal has been described as one of the signs of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmitral inflow and pulmonary vein flow patterns are complementary [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, restrictive mitral inflow is characterized by a short isovolumic relaxation time, a normal or slightly elevated peak velocity, a short deceleration time, and a low A wave velocity. These features result in an increased E to A ratio and a pattern known as \"pseudonormalization\" (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"     waveform 2",
"    </a>",
"    ). A restrictive pattern on mitral inflow and decreased systolic fraction on pulmonary vein inflow permit confident recognition of elevated filling pressure. A prolonged retrograde pulmonary venous A wave and a shortened A wave on mitral inflow also confirm elevated pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1034768875\">",
"    <span class=\"h2\">",
"     Tissue Doppler measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral e' and a' velocities can be measured during transesophageal echocardiography at the lateral annulus. These measurements have been validated and appear to reflect diastolic function independent of loading conditions. A study performed in the intensive care unit using both TEE and TTE showed that the sensitivities and specificities of estimating PCWP of 15 mmHg or higher were, respectively, 86 and 81 percent for lateral",
"    <span class=\"nowrap\">",
"     E/E'",
"    </span>",
"    above 7.5 and 76 and 80 percent for medial",
"    <span class=\"nowrap\">",
"     E/E'",
"    </span>",
"    above 9. After volume expansion, the",
"    <span class=\"nowrap\">",
"     E/E'",
"    </span>",
"    tracked the changes in wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13240/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       \"Patient information: Echocardiogram (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5894268\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transesophageal echocardiography (TEE) displays most of the LV with definition that is equal or superior to that achieved with transthoracic echocardiography. However, most TEE views do not fully display the apical portion of the LV, which is truncated or foreshortened. This shortcoming lowers the sensitivity of TEE for detecting a wall motion abnormality limited to the apex, leads to underrepresentation of chamber volume, and may result in misinterpretation of global LV systolic function. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While there are well validated quantitative methods to measure LV systolic function and ejection fraction when performing transthoracic echocardiography, most evaluation of the LV by TEE is qualitative. However, qualitative assessment of LV systolic function is generally accurate and has been validated. For the most thorough and accurate estimate of LV systolic function, a transgastric short-axis view of the LV should be obtained in addition to long-axis gastric views that approach the LV apex and demonstrate the basal inferior wall. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systolic function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TEE can be a useful modality for identifying regional wall motion abnormalities of the left ventricle associated with acute ischemia or prior infarction. (See",
"      <a class=\"local\" href=\"#H6508067\">",
"       'Evaluation of regional wall motion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LV diastolic function can also be evaluated with a combination of techniques, including the transmitral inflow pattern, pulmonary vein inflow, and tissue Doppler imaging. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diastolic function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19266383\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Nelson Schiller, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/1\">",
"      Beaupre PN, Roizen MF, Cahalan MK, et al. Hemodynamic and two-dimensional transesophageal echocardiographic analysis of an anaphylactic reaction in a human. Anesthesiology 1984; 60:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/2\">",
"      Leung JM, Levine EH. Left ventricular end-systolic cavity obliteration as an estimate of intraoperative hypovolemia. Anesthesiology 1994; 81:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/3\">",
"      Roizen MF, Beaupre PN, Alpert RA, et al. Monitoring with two-dimensional transesophageal echocardiography. Comparison of myocardial function in patients undergoing supraceliac, suprarenal-infraceliac, or infrarenal aortic occlusion. J Vasc Surg 1984; 1:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/4\">",
"      Mitchell MM, Prakash O, Rulf EN, et al. Nitrous oxide does not induce myocardial ischemia in patients with ischemic heart disease and poor ventricular function. Anesthesiology 1989; 71:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/5\">",
"      Kikura M, Ikeda K. Comparison of effects of sevoflurane/nitrous oxide and enflurane/nitrous oxide on myocardial contractility in humans. Load-independent and noninvasive assessment with transesophageal echocardiography. Anesthesiology 1993; 79:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/6\">",
"      Houltz E, Gustavsson T, Caidahl K, et al. Effects of surgical stress and volatile anesthetics on left ventricular global and regional function in patients with coronary artery disease. Evaluation by computer-assisted two-dimensional quantitative transesophageal echocardiography. Anesth Analg 1992; 75:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/7\">",
"      Smith MD, MacPhail B, Harrison MR, et al. Value and limitations of transesophageal echocardiography in determination of left ventricular volumes and ejection fraction. J Am Coll Cardiol 1992; 19:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/8\">",
"      Hozumi T, Shakudo M, Shah PM. Quantitation of left ventricular volumes and ejection fraction by biplane transesophageal echocardiography. Am J Cardiol 1993; 72:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/9\">",
"      Doerr HK, Qui&ntilde;ones MA, Zoghbi WA. Accurate determination of left ventricular ejection fraction by transesophageal echocardiography with a nonvolumetric method. J Am Soc Echocardiogr 1993; 6:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/10\">",
"      Urbanowicz JH, Shaaban MJ, Cohen NH, et al. Comparison of transesophageal echocardiographic and scintigraphic estimates of left ventricular end-diastolic volume index and ejection fraction in patients following coronary artery bypass grafting. Anesthesiology 1990; 72:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/11\">",
"      Royse CF, Royse AG. Afterload corrected fractional area change (FACac): a simple, relatively load-independent measurement of left ventricular contractility in humans. Ann Thorac Cardiovasc Surg 2000; 6:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/12\">",
"      Sutton DC, Cahalan MK. Intraoperative assessment of left ventricular function with transesophageal echocardiography. Cardiol Clin 1993; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/13\">",
"      Cahalan MK, Ionescu P, Melton HE Jr, et al. Automated real-time analysis of intraoperative transesophageal echocardiograms. Anesthesiology 1993; 78:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/14\">",
"      MacLaren G, Kluger R, Connelly KA, Royse CF. Comparative feasibility of myocardial velocity and strain measurements using 2 different methods with transesophageal echocardiography during cardiac surgery. J Cardiothorac Vasc Anesth 2011; 25:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/15\">",
"      Kukucka M, Nasseri B, Tscherkaschin A, et al. The feasibility of speckle tracking for intraoperative assessment of regional myocardial function by transesophageal echocardiography. J Cardiothorac Vasc Anesth 2009; 23:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/16\">",
"      Marwick TH, Leano RL, Brown J, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging 2009; 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/17\">",
"      Reckefuss N, Butz T, Horstkotte D, Faber L. Evaluation of longitudinal and radial left ventricular function by two-dimensional speckle-tracking echocardiography in a large cohort of normal probands. Int J Cardiovasc Imaging 2011; 27:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/18\">",
"      Ernande L, Rietzschel ER, Bergerot C, et al. Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr 2010; 23:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/19\">",
"      Muhiudeen IA, Kuecherer HF, Lee E, et al. Intraoperative estimation of cardiac output by transesophageal pulsed Doppler echocardiography. Anesthesiology 1991; 74:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/20\">",
"      Izzat MB, Regragui IA, Wilde P, et al. Transesophageal echocardiographic measurements of cardiac output in cardiac surgical patients. Ann Thorac Surg 1994; 58:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/21\">",
"      Stoddard MF, Prince CR, Ammash N, et al. Pulsed Doppler transesophageal echocardiographic determination of cardiac output in human beings: comparison with thermodilution technique. Am Heart J 1993; 126:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/22\">",
"      Kuecherer HF, Foster E. Hemodynamics by transesophageal echocardiography. Cardiol Clin 1993; 11:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/23\">",
"      Royse CF, Connelly KA, MacLaren G, Royse AG. Evaluation of echocardiography indices of systolic function: a comparative study using pressure-volume loops in patients undergoing coronary artery bypass surgery. Anaesthesia 2007; 62:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/24\">",
"      Beaupre PN, Kremer PF, Cahalan MK, et al. Intraoperative detection of changes in left ventricular segmental wall motion by transesophageal two-dimensional echocardiography. Am Heart J 1984; 107:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/25\">",
"      Leung JM, O'Kelly B, Browner WS, et al. Prognostic importance of postbypass regional wall-motion abnormalities in patients undergoing coronary artery bypass graft surgery. SPI Research Group. Anesthesiology 1989; 71:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/26\">",
"      van Daele ME, Sutherland GR, Mitchell MM, et al. Do changes in pulmonary capillary wedge pressure adequately reflect myocardial ischemia during anesthesia? A correlative preoperative hemodynamic, electrocardiographic, and transesophageal echocardiographic study. Circulation 1990; 81:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/27\">",
"      Akchurin RS, Tkachuk LM, Lepilin MG, et al. Intraoperative transesophageal echocardiography for detection of myocardial ischemia. Herz 1993; 18:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/28\">",
"      Rouine-Rapp K, Ionescu P, Balea M, et al. Detection of intraoperative segmental wall-motion abnormalities by transesophageal echocardiography: the incremental value of additional cross sections in the transverse and longitudinal planes. Anesth Analg 1996; 83:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/29\">",
"      Shah PM, Kyo S, Matsumura M, Omoto R. Utility of biplane transesophageal echocardiography in left ventricular wall motion analysis. J Cardiothorac Vasc Anesth 1991; 5:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/30\">",
"      Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/31\">",
"      Foster E, O'Kelly B, LaPidus A, et al. Segmental analysis of resting echocardiographic function and stress scintigraphic perfusion: implications for myocardial viability. Am Heart J 1995; 129:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/32\">",
"      Nishimura RA, Housmans PR, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part I. Physiologic and pathophysiologic features. Mayo Clin Proc 1989; 64:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/33\">",
"      Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part II. Clinical studies. Mayo Clin Proc 1989; 64:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/34\">",
"      Gorcsan J 3rd, Diana P, Lee J, et al. Reversible diastolic dysfunction after successful coronary artery bypass surgery. Assessment by transesophageal Doppler echocardiography. Chest 1994; 106:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/35\">",
"      Hoit BD, Shao Y, Gabel M, Walsh RA. Influence of loading conditions and contractile state on pulmonary venous flow. Validation of Doppler velocimetry. Circulation 1992; 86:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/36\">",
"      Kuecherer HF, Muhiudeen IA, Kusumoto FM, et al. Estimation of mean left atrial pressure from transesophageal pulsed Doppler echocardiography of pulmonary venous flow. Circulation 1990; 82:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/37\">",
"      Kuecherer HF, Kusumoto F, Muhiudeen IA, et al. Pulmonary venous flow patterns by transesophageal pulsed Doppler echocardiography: relation to parameters of left ventricular systolic and diastolic function. Am Heart J 1991; 122:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/38\">",
"      Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Relation of pulmonary vein to mitral flow velocities by transesophageal Doppler echocardiography. Effect of different loading conditions. Circulation 1990; 81:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/39\">",
"      Barbier P, Solomon S, Schiller NB, Glantz SA. Determinants of forward pulmonary vein flow: an open pericardium pig model. J Am Coll Cardiol 2000; 35:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/40\">",
"      Barbier P, Solomon SB, Schiller NB, Glantz SA. Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function. Circulation 1999; 100:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/41\">",
"      Rossvoll O, Hatle LK. Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures. J Am Coll Cardiol 1993; 21:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/42\">",
"      Ali MM, Royse AG, Connelly K, Royse CF. The accuracy of transoesophageal echocardiography in estimating pulmonary capillary wedge pressure in anaesthetised patients. Anaesthesia 2012; 67:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/43\">",
"      Klein AL, Stewart WJ, Bartlett J, et al. Effects of mitral regurgitation on pulmonary venous flow and left atrial pressure: an intraoperative transesophageal echocardiographic study. J Am Coll Cardiol 1992; 20:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13240/abstract/44\">",
"      Combes A, Arnoult F, Trouillet JL. Tissue Doppler imaging estimation of pulmonary artery occlusion pressure in ICU patients. Intensive Care Med 2004; 30:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5294 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13240=[""].join("\n");
var outline_f12_59_13240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5894268\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTOLIC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ejection fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fractional area change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1034768788\">",
"      Strain analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6508067\">",
"      Evaluation of regional wall motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6508074\">",
"      - Views used for evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6508081\">",
"      - Measurement of wall motion abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6508088\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIASTOLIC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mitral inflow filling pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary venous Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1034768875\">",
"      Tissue Doppler measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5894268\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19266383\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5294\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5294|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/4/16463\" title=\"diagnostic image 1\">",
"      Lateral CXR barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/35/17970\" title=\"diagnostic image 2A\">",
"      CW Doppler pulmonary vein MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/57/34704\" title=\"diagnostic image 2B\">",
"      Doppler pulmonary vein MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5294|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/21/1360\" title=\"figure 1A\">",
"      LV wall motion analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/26/33184\" title=\"figure 1B\">",
"      2 D views coronary perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/8/38029\" title=\"figure 2A\">",
"      Pulmonary vein velocity schematic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/1/27671\" title=\"figure 2B\">",
"      Pulsed wave Doppler pulmonary venous flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5294|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/33/28177\" title=\"waveform 1A\">",
"      LV Doppler flow patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/31/5618\" title=\"waveform 1B\">",
"      Doppler transmitral inflow pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/45/32470\" title=\"waveform 2\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31878?source=related_link\">",
"      Transesophageal echocardiography in traumatic rupture of the aortic isthmus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_59_13241="EPS tracing VT initiation termination";
var content_f12_59_13241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Electrophysiology study (EPS) in a patients showing the initiation and termination of ventricular tachycardia (VT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (1,2,and V1) and electrogram from the coronary sinus (CS), bundle of His (HBE) and right ventricular apex (RVA). During ventricular pacing (S1) two premature ventricular beats (S2,S3) induce a sustained monomorphic ventricular tachycardia (VT) with a cycle length (CL) of 340 msec; the HBE tracing shows AV dissociation and the left atrial (LA) electrograms occur at a slower rate than those from the left ventricle (LV) (panel A). Panel B shows termiantion of the VT by the addition of a four beat train of rapid ventricular pacing (RVP), using a cycle length (230 msec) that is shorter than than of the VT (330 msec). The resumption of normal sinus rhythm (NSR) is indicated by the presence of the normal sequence of electrograms, ie, atrial (A), bundle of His (H) and ventricular (V).",
"    <div class=\"footnotes\">",
"     S: stimulus artifact.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13241=[""].join("\n");
var outline_f12_59_13241=null;
var title_f12_59_13242="Emerging therapies for hepatic fibrosis";
var content_f12_59_13242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emerging therapies for hepatic fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13242/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13242/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13242/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/59/13242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/59/13242/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/59/13242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic fibrosis is a scarring response to liver damage, which may be considered beneficial since it can encapsulate injury. However, in doing so liver function may ultimately become impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been exciting progress in understanding hepatic fibrosis, which represents a paradigm for wound healing in other tissues, including skin, lung, and kidney, since it involves many of the same cell types and mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An understanding of these mechanisms has a number of clinical implications, including the development of interventions designed to impede or reverse hepatic fibrosis, some of which are already available. This topic review will focus on possible future treatments aimed at impeding or reversing fibrosis. The pathogenesis of hepatic fibrosis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIBROSIS REVERSIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact moment at which fibrosis becomes irreversible is unknown, either in terms of a histologic marker or a specific change in the matrix composition or content. Dense cirrhosis with nodule formation, portal hypertension, and early liver failure is generally considered irreversible, but less advanced lesions can show remarkable reversibility when the underlying cause of the liver injury is controlled and possibly by other therapeutic interventions.",
"   </p>",
"   <p>",
"    The development of targeted therapies is moving closer to reality (",
"    <a class=\"graphic graphic_table graphicRef50384 \" href=\"UTD.htm?35/37/36444\">",
"     table 1",
"    </a>",
"    ). The ideal drug would be the one which could be easily delivered, is well tolerated, has high liver specificity, and promotes the resorption of excess interstitial matrix without abolishing the salutary effects of the normal hepatic ECM. The hope is not necessarily to eliminate fibrosis entirely, but rather to attenuate its development so that patients with chronic liver disease do not succumb to the end organ failure that it creates (eg, portal hypertension, ascites, liver failure). While no therapy yet meets these goals, the framework for developing such treatments is in place.",
"   </p>",
"   <p>",
"    As a general rule, the currently available antifibrotic therapies have been directed against suppressing hepatic inflammation rather than subduing fibrosis. In the future, targeting of stellate cells and fibrogenic mediators will be a mainstay of therapy. Points of therapeutic intervention may include efforts to remove the injurious stimuli, suppress hepatic inflammation, downregulate stellate cell activation, and promote matrix degradation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REMOVE INJURIOUS STIMULI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removing the underlying cause of liver injury is the most effective way to prevent fibrosis. This approach can be highly effective when instituted early. Examples include removal of excess iron or copper in genetic hemochromatosis or Wilson's disease, respectively, abstinence in alcoholic liver disease, anthelminthic therapy in schistosomiasis, clearance of HBV or HCV in chronic viral hepatitis, and biliary decompression in bile duct obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. In the future, identification of the pathogenetic mechanisms underlying primary biliary cirrhosis or sclerosing cholangitis may permit the elimination of bile duct injury and periductular fibrosis. Discontinuation of hepatotoxic drugs may prevent progression of drug-induced liver injury and fibrosis.",
"   </p>",
"   <p>",
"    Because of the high worldwide prevalence of HBV or HCV, there are public health efforts underway to clear these viruses in chronically infected patients. Exciting data have established that clearance of hepatitis C can lead to remarkable improvement in liver histology and clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Improvement may be associated with reduced hepatic venous pressure gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/9\">",
"     9",
"    </a>",
"    ], which is an important determinant of decompensation risk in patients with advanced liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/10\">",
"     10",
"    </a>",
"    ]. An improved clinical outcome is much more likely in patients who demonstrate some decrease in fibrosis after HCV clearance, compared with those with no evidence of decreased fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, sustained suppression of HBV with oral antiviral therapies has been associated with remarkable histologic improvement. In an illustrative study, more than 70 percent of patients on long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    showed improvement in fibrosis scores over a 240-week treatment period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/11\">",
"     11",
"    </a>",
"    ]. Similar observations were made in a study of patients with chronic HBV treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/12\">",
"     12",
"    </a>",
"    ]. Fibrosis and cirrhosis may also be substantially improved with interferon therapy in patients with delta hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/13\">",
"     13",
"    </a>",
"    ]. One study found that HBV genotype C was associated accelerated fibrosis compared with other genotypes, possibly warranting earlier treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, with the growing use of bariatric surgery in morbid obesity, evidence of reduced fibrogenesis and improved fibrosis has begun to emerge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUPPRESS HEPATIC INFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory mediators may stimulate stellate cell activation in chronic liver diseases such as viral or autoimmune hepatitis and drug-induced liver injury. Thus, antiinflammatory medications might be beneficial in preventing fibrosis in these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids have been a mainstay of therapy for many inflammatory liver diseases. As an example, they can induce clinical remission and improve hepatic histopathology in patients with autoimmune hepatitis, even those with advanced histologic features. However, the incomplete suppression of fibrogenesis and undesirable side effects after prolonged administration limit its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1924106232\">",
"    <span class=\"h2\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic evidence has consistently revealed a protective effect of caffeine on fibrosis among patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. While not strictly an anti-fibrotic, experimental data suggest that adenosine blockade, which is one of the effects of caffeine, may limit fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is an antiinflammatory drug but its value in treating chronic liver disease is unproven. In clinical trials of patients with primary biliary cirrhosis, colchicine improved laboratory values but mortality and transplantation rate were unaffected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .) In another trial, colchicine improved overall survival of patients with cirrhosis but did not reduce the mortality related specifically to liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite the uncertainty and lack of convincing data, colchicine is still being used by some physicians. One study suggested that its metabolite, colchiceine, may have better antifibrotic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/20\">",
"     20",
"    </a>",
"    ]. However, a meta-analysis of colchicine trials showed no benefit and thus it cannot be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malotilate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malotilate is an experimental antiinflammatory agent that has hepatoprotective effects and reduces fibrogenesis in experimental liver injury due to CCl4 or dimethylnitrosamine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, no clear benefit has been observed in human trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA) has clear efficacy in primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Although no direct antifibrotic effect of UDCA is established in humans, a benefit in a rat model of bile duct ligation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another antiinflammatory strategy is to neutralize inflammatory cytokines using specific receptor antagonists. As an example, antagonists to TNF-alpha were studied in alcoholic hepatitis but were associated with increased mortality, possibly because of an increased risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interleukin 10",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small uncontrolled trial in 24 patients with HCV infection and fibrosis, treatment with interleukin-10 was associated with dramatic antifibrogenic and antiinflammatory activity in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/28\">",
"     28",
"    </a>",
"    ]. However, a large multicenter randomized controlled trial showed no benefit, and in fact enhanced viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMUNE MODULATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     NK cell stimulation/immunomodulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells are members of the innate immune system and account for 50 percent of the lymphoid pool in the liver. In addition to aiding in defense against viral infections, NK cells can ameliorate hepatic fibrosis by killing activated stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This process is associated with the release of two antifibrotic cytokines, interferon-alpha and interferon-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Interestingly, alcohol has a dampening effect on these antifibrotic qualities of NK cells, which could account for the accelerated fibrosis in the setting of alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, new approaches to antifibrotic therapies could exploit strategies that foster and promote NK cell surveillance or activate downstream signaling pathways that NK cells use to clear activated stellate cells. Experimental studies in rodents support this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], but any human studies of this type are years away.",
"   </p>",
"   <p>",
"    More recently, dendritic cells have also been implicated in the pathogenesis of fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, they may represent another immune cell type that could be a target for antifibrotic therapies.",
"   </p>",
"   <p>",
"    Because Jun Kinase regulates many inflammatory pathways in liver injury, antagonism of this intracellular signaling mediator has generated interest, a prospect supported by animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hepatoprotection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively new class of drugs, broadly referred to as \"hepatoprotectants\", is showing considerable promise in preclinical and clinical studies. This includes hepatocyte growth factor (HGF), HGF deletion variants, and HGF synthetic and insulin-like growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. In addition, a small molecule caspase inhibitor improved AST levels in patients with chronic HCV and is currently in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/43\">",
"     43",
"    </a>",
"    ]. Although caspase inhibitors have the potential to reduce hepatic injury, there are no ongoing trials using this class of drugs due to reports of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/44\">",
"     44",
"    </a>",
"    ] or toxicity in preclinical (ie, animal) studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hepatocyte growth factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong support for the antifibrotic effect of HGF in animal models of fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Mechanisms of its antifibrotic activity include suppression of TGF-beta, induction of collagenase expression, growth inhibition and apoptosis of HSCs, and blocking of biliary epithelial cells from undergoing epithelial-to-mesenchymal transition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/39,40,47\">",
"     39,40,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HGF also appears to inhibit TGF-beta from activating its downstream targets, thereby suppressing TGF-beta mediated transcription of collagen type I in activated HSCs. This effect is mediated by increased interaction between galectin-7 and phosphorylated Smad3, effectively sequestering the p-Smad3 to the cytoplasm and preventing collagen promoter activation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/48\">",
"     48",
"    </a>",
"    ]. Although animal studies of HGF clearly demonstrate its antifibrotic potential, because it is a mitogen there remains concern that it could promote carcinogenesis in the long term. On the other hand, there are data suggesting that HGF could act as a tumor suppressor based on an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/49\">",
"     49",
"    </a>",
"    ]. Thus, further studies are expected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Caspase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis of hepatocytes is recognized as an inflammatory stimulus that is profibrogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. As a result, small molecules have been developed that specifically block caspases, key intracellular effectors of apoptotic signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/54\">",
"     54",
"    </a>",
"    ]. The main theoretical concern is that blocking this pathway (which removes cells that may have acquired DNA damage) will lead to an increased risk of malignancy. Recent clinical trials of these agents have been halted, although no significant adverse toxicity had been reported in patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Farnesoid X receptor ligands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The farnesoid X receptor (FXR) is a member of the nuclear receptor transcription factor family that can be activated by binding of bile acids. Chenodeoxycholic acid (CDCA) is the most active endogenous ligand. FXR has been implicated in regulating genes controlling bile flow and secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. An additional, novel role for FXR was uncovered with its identification in stellate cells, where it downregulates cellular activation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/57\">",
"     57",
"    </a>",
"    ]. In these studies, CDCA showed a significant antifibrotic effect in animal models. FXR ligands may also reduce stellate cell contractility, raising the potential for attenuating portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo and in vitro evidence suggested that FXR ligands upregulate small heterodimer partner (SHP) in HSCs, and markedly reduce collagen I levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, the FXR-SHP cascade effectively inhibits TIMP-1 expression in stellate cells, mediated by interaction of SHP with JunD, resulting in the inability of JunD to bind the TIMP-1 promoter. MMP-2 activity levels are also increased by 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inhibition of TIMP-1 is pivotal for two reasons: first, metalloprotease activity will no longer be inhibited, and second, stellate cells lose the crucial survival signals they receive from TIMP-1 (see above). Interestingly, FXR ligands can reverse the downregulation of PPAR-gamma in stellate cells in models of rodent liver fibrosis (porcine serum, CCl(4) and bile duct ligation), and submaximal effective doses of PPAR-gamma agonists and FXR ligands synergistically reduce levels of collagen type I [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/60\">",
"     60",
"    </a>",
"    ]. Combination targeting of these two pathways could reduce the likelihood of side effects resulting from higher doses of a PPAR-gamma agonist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DOWNREGULATE STELLATE CELL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression or reversal of stellate cell activation has inherent attractiveness as a therapeutic strategy because of the central role that stellate cells have in fibrogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antifibrotic effects of the interferons were anticipated because they downregulate collagen gene transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/32\">",
"     32",
"    </a>",
"    ]. This effect was hypothesized to explain the improvement in fibrosis seen in some studies of patients with HCV treated with interferon who did not achieve a sustained virologic response. Unfortunately, such a benefit was not confirmed in a large, multicenter clinical trial of maintenance interferon therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon gamma is another interferon that has inhibitory effects on hepatic stellate cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/33\">",
"     33",
"    </a>",
"    ]. It also reduces the expression of mRNAs of type I and IV collagen as well as fibronectin in activated hepatic stellate cells grown in tissue culture, inhibits stellate cell proliferation, and reduces smooth muscle actin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/33\">",
"     33",
"    </a>",
"    ]. However, a randomized controlled trial was also negative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cannabinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabinoids have emerged as an attractive pathway for antagonizing hepatic fibrosis. There are two identified cannabinoid receptors (CB1 and CB2), both of which are G-protein-coupled receptors.",
"   </p>",
"   <p>",
"    The CB1 receptor is induced primarily in hepatic stellate cells as they activate into myofibroblasts during liver injury. Antagonism of CB1 in an acute model of injury due to CCl(4) or in isolated cells leads to decreased expression of TGF-beta-1 (the most potent fibrogenic cytokine), reduced cellular proliferation, and increased myofibroblast apoptosis, all of which would effectively reduce fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/63\">",
"     63",
"    </a>",
"    ]. Clinical trials of the drug rimonabant, a CB1 antagonist, were halted, and the drug was withdrawn from the market due to a high incidence of severe depression, a predictable consequence of central CB1 blockade. However, the development of peripheral CB1 receptor antagonists that do not cross the blood brain barrier has led to renewed enthusiasm for antagonizing CB1 signaling in liver [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in human stellate cells demonstrate that activation of CB2 is antifibrogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/65\">",
"     65",
"    </a>",
"    ]. Stimulation of cultured stellate cells with an endogenous cannabinoid, anandamide, provokes stellate cell death, albeit through a CB2 ligand-independent pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/66\">",
"     66",
"    </a>",
"    ]. In contrast to CB1 signaling, the CB2 pathway is antifibrotic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/65\">",
"     65",
"    </a>",
"    ]. Thus, agonists rather than antagonists to this pathway can reduce collagen accumulation in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, endogenous opioids, like cannabinoids, have profibrogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, opioid antagonists have been examined in animal models, where they demonstrate antifibrotic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidative stress is an important stimulus to stellate cell activation providing a rationale for the use of antioxidants such as vitamin E to suppress fibrogenesis. Limited data with vitamin E suggest efficacy in experimental conditions, although discordant data have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/70\">",
"     70",
"    </a>",
"    ]. Trials in humans are currently underway. Some studies have documented inhibition of stellate cell activation by other antioxidants such as resveratrol, quercetin, and N-acetylcysteine (NAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/71\">",
"     71",
"    </a>",
"    ]. As will be discussed below, the antifibrotic properties of flavonoid compounds rely heavily upon their antioxidative effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Silymarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silymarin (silybum marianum) is a natural component of milk thistle, which has exhibited promising antifibrotic activity in experimental liver injury and is widely used as a non-prescription agent in patients with chronic liver disease, particularly those with HCV. Based upon its structure, silymarin belongs to a group of flavonoid compounds, the other members of which include quercetin, baicalin, and baicalein (see below). These flavonoids have drawn increasing attention because of their antifibrogenic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/72\">",
"     72",
"    </a>",
"    ]. Silymarin functions as an antioxidant and may decrease hepatic injury via cytoprotection and inhibition of Kupffer cell function. A related compound, silibinin, is also antifibrotic in cultured stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, despite its theoretical benefit and efficacy in cultured cells, a systematic review that included 14 studies found no clear evidence showing a reduction in mortality, improvement in liver histology, or biochemical markers of liver function in patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/74\">",
"     74",
"    </a>",
"    ]. Similar conclusions were reached in an evidence report on the efficacy of milk thistle in liver disease performed through the Agency for Healthcare Research and Quality (",
"    <a class=\"external\" href=\"file://www.ahrq.gov/\">",
"     www.ahrq.gov",
"    </a>",
"    ). However, an intravenous form is still being studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"     \"Investigational therapies for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receptors for angiotensin II on hepatic stellate cells are upregulated during activation, leading to increased proliferation and contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Stimulation of angiotensin II in cultured active hepatic cells increases generation of reactive oxygen species, the secretion of inflammatory and fibrogenic cytokines, cell growth, migration, and fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/75,77\">",
"     75,77",
"    </a>",
"    ]. Furthermore, in vitro and animal studies have demonstrated that angiotensin II antagonists have antifibrotic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The renin-angiotensin system may also amplify inflammation through generation of oxidant stress. As a result, the angiotensin converting enzyme antagonists",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensinogen II type I receptor antagonists may have antiinflammatory and antifibrogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/78,80,81\">",
"     78,80,81",
"    </a>",
"    ]. These drugs are particularly appealing as antifibrotic therapies because of the large amount of preclinical data establishing proof of concept [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], combined with a strong safety record in clinical use for other indications. Moreover, efforts to target drugs in this class specifically to liver add to their appeal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/84\">",
"     84",
"    </a>",
"    ]. The strongest factor limiting the development of angiotensin signaling antagonists is the large number of different compounds within this class already, making it less appealing for pharmaceutical companies to invest in clinical trials with these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cytokine-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modulation of cytokine activity represents a relatively feasible and specific approach. Potential strategies include the use of receptor antagonists and cytokine antibodies (which inhibit the production or activation of cytokines) and using cytokines or proteins that promote extracellular matrix resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     TGF-beta antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;TGF-beta is a major fibrogenic cytokine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TGF-beta antagonists are being extensively tested because neutralizing this potent cytokine would have the dual effect of inhibiting matrix production and accelerating its degradation. Animal and culture studies using soluble TGF-beta receptors or other means of neutralizing the cytokine including monoclonal antibodies and protease inhibitors to block TGF-beta activation have established proof-of-principle for these approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. The natural compound curcumin may also block TGF-beta signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. A number of novel TGF-beta antagonists are also being developed and may undergo testing soon. These could include recombinant Smad7, which antagonizes TGF-beta activity in stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/91\">",
"     91",
"    </a>",
"    ]. A concern related to inhibiting TGF-beta is that it may promote inflammation and hepatocellular growth or reduce apoptosis, the clinical consequences of which will need to be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Endothelin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin receptor antagonists have also been tested as antifibrotic agents and are among the most promising, because agents of this type are already undergoing clinical trials for hypertensive diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/92\">",
"     92",
"    </a>",
"    ]. One agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    , is antifibrotic and reduces stellate cell activation in experimental fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/93\">",
"     93",
"    </a>",
"    ]. Bosentan is potentially hepatotoxic but a related drug, tezosentan, may have a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cytokine antagonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many proliferative cytokines, including platelet derived growth factor (PDGF), fibroblast growth factor (FGF), and TGF-alpha, signal through tyrosine kinase receptors, inhibitors of which are already undergoing clinical trials in other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/94\">",
"     94",
"    </a>",
"    ]. Because the intracellular signaling pathways for these receptors are well understood, inhibitors to signaling molecules are being explored in vivo or in cultured stellate cells. Antagonists to a range of pathways are under evaluation that block PDGF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/95,96\">",
"     95,96",
"    </a>",
"    ] or VEGF receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/97\">",
"     97",
"    </a>",
"    ], and compounds that modulate intracellular cyclic AMP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/98\">",
"     98",
"    </a>",
"    ] or block ion transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/99\">",
"     99",
"    </a>",
"    ]. Among these many approaches, drugs that are already developed for other indications have particular appeal because their potential adverse effects are well known and the likelihood of approval for a new indication is greater than for a new molecular entity not previously administered to patients. One clear example is sorafenib, a drug that is now approved for hepatocellular carcinoma but appears to have antifibrotic activity in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success in developing Gleevec, a safe, effective small molecule tyrosine kinase antagonist in human leukemia and mesenchymal cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/102,103\">",
"     102,103",
"    </a>",
"    ], supports the potential of this approach in other indications, including liver fibrosis. In fact, Gleevec is antifibrotic in experimental liver fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/104\">",
"     104",
"    </a>",
"    ], albeit only in ongoing rather than established fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/105\">",
"     105",
"    </a>",
"    ]. Furthermore, combinations of Gleevec with other antifibrotics may be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/95\">",
"     95",
"    </a>",
"    ]. A similar rationale underlies the potential use of sorafenib (a multikinase inhibitor approved for the treatment hepatocellular carcinoma) as an antifibrotic, based upon encouraging animal data [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/101,106\">",
"     101,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other orally available, low molecular weight small molecules are under development to block cytokine receptors or intracellular signaling. One such compound is a selective inhibitor of Rho-mediated focal adhesions, which can reduce experimental liver fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/107\">",
"     107",
"    </a>",
"    ]. Antisense [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/108\">",
"     108",
"    </a>",
"    ] and a monoclonal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/109\">",
"     109",
"    </a>",
"    ] to PDGF beta chain also block experimental hepatic fibrosis. Since siRNA technology is increasingly becoming clinically applicable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/110\">",
"     110",
"    </a>",
"    ], this approach merits further evaluation.",
"   </p>",
"   <p>",
"    Inhibition of matrix production has been the primary target of most antifibrotic therapies to date. This has been attempted directly by blocking matrix synthesis and processing, or indirectly by inhibiting the activity of TGF-beta-1, the major fibrogenic cytokine. The emerging importance of translational regulation of collagen gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/111-114\">",
"     111-114",
"    </a>",
"    ] could lead to specific translational inhibitors with therapeutic value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Herbal compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Asian countries such as China, herbal medicines have been used for centuries to treat liver diseases. Some studies have elucidated the cellular mechanisms of several herbal medicines, which have putative activity against liver fibrosis. Sho-saiko-to (Xiao-Chaihu-Tang), one of the most prominent herbal medicines, inhibits stellate cell activation and reduces fibrosis in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Administration of Sho-saiko-to in experimental liver fibrosis reduced hepatic type I and III collagen expression and hydroxyproline content. It also decreased the number of alpha-smooth muscle actin positive stellate cells and increased retinoid concentration in injured liver. The antifibrotic mechanism of sho-saiko-to may include an antioxidative activity in which baicalin and baicalein are active components [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another herbal medicine under study is salvia miltiorrhiza (Dan-shen), which also inhibits fibrosis in animal model and downregulates mRNA expression of TGF-beta-1, pro-collagen I and III [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/118\">",
"     118",
"    </a>",
"    ]. Apart from the scientific insight they provide, these studies underscore the potential value of traditional medicine, a system which has been used for centuries in many parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/115\">",
"     115",
"    </a>",
"    ]. Traditional therapies could lead to innovative strategies for treating hepatic fibrosis and cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1924106440\">",
"    <span class=\"h2\">",
"     Epigenetic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;New data are emerging that stellate cell activation is regulated in part by epigenetic pathways (ie, events that alter genome activity without affecting the sequence of DNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. Epigenetic pathways may be particularly amenable to therapeutic manipulation not only in cancer, but also in non-malignant diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Promote matrix degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The promotion of matrix degradation is of special clinical significance given the need to resorb matrix in patients with established fibrosis. Advances in understanding of matrix degradation in liver are likely to translate into new approaches to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/122\">",
"     122",
"    </a>",
"    ]. As an example, preventing the upregulation of TIMP-1 and -2 during stellate cell activation might increase matrix degradation in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/122\">",
"     122",
"    </a>",
"    ]. Administration of an antibody against TIMP-1 attenuated carbon tetrachloride-induced liver fibrosis in rats [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/123\">",
"     123",
"    </a>",
"    ]. Strategies to increase the activity of matrix degrading enzymes or to introduce degrading enzymes with gene therapy are also of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. TGF-beta antagonists can stimulate matrix degradation by downregulating TIMPs and increasing the net activity of interstitial collagenase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     TIMP antagonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIMP-1 has an important role in stellate cell survival by directly inhibiting apoptosis of these cells. In support of the role of TIMP in vivo, transgenic overexpression of TIMP-1 in the liver delays regression of liver fibrosis in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/126\">",
"     126",
"    </a>",
"    ]. Thus, as described further below, TIMP antagonism represents an attractive antifibrotic target. The pro-survival effect of TIMP-1 depends upon MMP inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/127\">",
"     127",
"    </a>",
"    ]. Transgenic overexpression of TIMP-1 in mouse models of fibrosis leads to delayed regression, and is accompanied by decreased numbers of apoptotic stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/126\">",
"     126",
"    </a>",
"    ]. By contrast, antibodies to TIMP can attenuate fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/123\">",
"     123",
"    </a>",
"    ]. Similarly, use of MMP-9 mutant proteins to sequester TIMP-1 molecules reduces fibrosis accumulation by enhancing matrix resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Promote stellate cell apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promoting apoptosis of activated stellate cells is another potential strategy in theory, but is not yet feasible in practice. Obstacles to this approach include the need to target stellate cells and to titrate the apoptotic effect to avoid loss of normal cells. Furthermore, a coherent understanding of apoptosis in stellate cells is still developing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Apoptosis can be induced by disruption of integrin-mediated adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Targeted pro-apoptotic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention is increasingly focused on how liver fibrosis regresses, and in particular the fate of activated stellate cells as fibrosis recedes. Mounting evidence indicates that both reversal of the activated stellate cell phenotype and apoptosis are possible. In particular, as liver fibrosis regresses, there is selective death of activated stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/132\">",
"     132",
"    </a>",
"    ]. This exciting observation has led to animal studies using gliotoxin, which provokes selective apoptosis of stellate cells in culture and in vivo, leading to reduced fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/133,134\">",
"     133,134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, inhibition of I kappa B kinase (Ikk), whose net effect is to increase nuclear factor kappa B (NFkB) signaling in stellate cells, may accelerate apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/135\">",
"     135",
"    </a>",
"    ]. Apoptosis can also be provoked by disruption of integrin-mediated adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/136\">",
"     136",
"    </a>",
"    ] or through use of TRAIL ligands [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/137\">",
"     137",
"    </a>",
"    ]. Stellate cells contain several families of apoptotic mediators, including",
"    <span class=\"nowrap\">",
"     Fas/FasL,",
"    </span>",
"    TNF receptors, nerve growth factor receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/138\">",
"     138",
"    </a>",
"    ], and",
"    <span class=\"nowrap\">",
"     Bcl/Bax,",
"    </span>",
"    so that additional targets to promote apoptosis will likely be uncovered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/139\">",
"     139",
"    </a>",
"    ]. Interestingly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , a widely prescribed statin, reportedly attenuated early fibrosis in a rodent model of biliary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/140\">",
"     140",
"    </a>",
"    ]. Whether or not this finding has clinical relevance is uncertain.",
"   </p>",
"   <p>",
"    Efforts to target therapies specifically to activated stellate cells have begun to succeed. A study using a vitamin A-containing liposome to deliver an siRNA to a collagen heat shock protein (Hsp47) has shown remarkable specificity in three different animal models of liver fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/110,141\">",
"     110,141",
"    </a>",
"    ]. This impressive stellate cell targeting could be exploited for a range of therapies to limit collateral injury to other cell types, or to deliver diagnostic imaging agents to liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Increase the degradation of scar matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;This component of treatment is important because antifibrotic therapy in human liver disease will need to provoke resorption of existing matrix in addition to preventing deposition of new scar. Direct expression of metalloproteinases in animal models of hepatic fibrosis has begun to confirm that matrix can be resorbed by expression of exogenous enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. In addition, an experimental study has confirmed the importance of matrix degradation in the regression of hepatic fibrosis by demonstrating that a genetically altered mouse expressing mutant collagen resistant to degradation displays delayed regression of fibrosis following liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/59/13242/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     FUTURE PROSPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the dramatic advances of the past decade, there is reason for optimism about the prospects for antifibrotic therapy. There is clear-cut evidence from successful antiviral trials that the liver has a capacity to resorb scar far in excess of what was previously believed possible.",
"   </p>",
"   <p>",
"    A major turning point in the establishment of this new field of fibrosis therapies will be the completion of a successful proof-of-principle trial. This success is likely to be built around more accurate and less invasive endpoints of clinical trials, which currently remain the single biggest limitation in the implementation of clinical trials for fibrosis therapy, since many attractive candidate compounds are available for testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116516461\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The exact moment at which hepatic fibrosis becomes irreversible is unknown, either in terms of a histologic marker or a specific change in the matrix composition or content.",
"     </li>",
"     <li>",
"      Currently available antifibrotic therapies have been directed against suppressing hepatic inflammation rather than subduing fibrosis.",
"     </li>",
"     <li>",
"      In the future, targeting of stellate cells and fibrogenic mediators will be a mainstay of therapy. Points of therapeutic intervention may include efforts to remove the injurious stimuli, suppress hepatic inflammation, downregulate stellate cell activation, and promote matrix degradation.",
"     </li>",
"     <li>",
"      The development of such targeted therapies is moving closer to reality (",
"      <a class=\"graphic graphic_table graphicRef50384 \" href=\"UTD.htm?35/37/36444\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/1\">",
"      Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/2\">",
"      Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/3\">",
"      Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/4\">",
"      Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/5\">",
"      Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/6\">",
"      Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/7\">",
"      Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/8\">",
"      Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/9\">",
"      Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007; 5:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/10\">",
"      Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/11\">",
"      Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/12\">",
"      Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/13\">",
"      Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/14\">",
"      Chan HL, Wong GL, Tse CH, et al. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol 2009; 7:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/15\">",
"      Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/16\">",
"      Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/17\">",
"      Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/18\">",
"      Chan ES, Montesinos MC, Fernandez P, et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 2006; 148:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/19\">",
"      Kershenobich D, Vargas F, Garcia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/20\">",
"      Rodr&iacute;guez L, Cerb&oacute;n-Ambriz J, Mu&ntilde;oz ML. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 1998; 29:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/21\">",
"      Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2001; :CD002148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/22\">",
"      Ala-Kokko L, Stenb&auml;ck F, Ryh&auml;nen L. Preventive effect of malotilate on carbon tetrachloride-induced liver damage and collagen accumulation in the rat. Biochem J 1987; 246:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/23\">",
"      Ala-Kokko L, Stenb&auml;ck F, Ryh&auml;nen L. Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat. J Lab Clin Med 1989; 113:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/24\">",
"      Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/25\">",
"      Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/26\">",
"      Poo JL, Feldmann G, Erlinger S, et al. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 1992; 102:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/27\">",
"      Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/28\">",
"      Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/29\">",
"      Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/30\">",
"      Melhem A, Muhanna N, Bishara A, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/31\">",
"      Radaeva S, Sun R, Jaruga B, et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/32\">",
"      Inagaki Y, Nemoto T, Kushida M, et al. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003; 38:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/33\">",
"      Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 1994; 42:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/34\">",
"      Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008; 134:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/35\">",
"      Horani A, Muhanna N, Pappo O, et al. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 292:G628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/36\">",
"      Muhanna N, Abu Tair L, Doron S, et al. Amelioration of hepatic fibrosis by NK cell activation. Gut 2011; 60:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/37\">",
"      Connolly MK, Bedrosian AS, Mallen-St Clair J, et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009; 119:3213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/38\">",
"      Kluwe J, Pradere JP, Gwak GY, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/39\">",
"      Kim WH, Matsumoto K, Bessho K, Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 2005; 166:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/40\">",
"      Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/41\">",
"      Masunaga H, Fujise N, Shiota A, et al. Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries. Eur J Pharmacol 1998; 342:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/42\">",
"      Sanz S, Pucilowska JB, Liu S, et al. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005; 54:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/43\">",
"      Valentino KL, Gutierrez M, Sanchez R, et al. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 2003; 41:441.",
"     </a>",
"    </li>",
"    <li>",
"     www.hivandhepatitis.com/2010_conference/easl/docs/0423_2010_b.html (Accessed on June 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/45\">",
"      Matsuda Y, Matsumoto K, Ichida T, Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem 1995; 118:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/46\">",
"      Yasuda H, Imai E, Shiota A, et al. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996; 24:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/47\">",
"      Ozaki I, Zhao G, Mizuta T, et al. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol 2002; 36:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/48\">",
"      Inagaki Y, Higashi K, Kushida M, et al. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 2008; 134:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/49\">",
"      Santoni-Rugiu E, Preisegger KH, Kiss A, et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A 1996; 93:9577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/50\">",
"      Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/51\">",
"      Feldstein A, Gores GJ. Steatohepatitis and apoptosis: therapeutic implications. Am J Gastroenterol 2004; 99:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/52\">",
"      Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/53\">",
"      Canbay A, Kip SN, Kahraman A, et al. Apoptosis and fibrosis in non-alcoholic fatty liver disease. Turk J Gastroenterol 2005; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/54\">",
"      Canbay A, Feldstein A, Baskin-Bey E, et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004; 308:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/55\">",
"      Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett 2008; 582:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/56\">",
"      Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol 2007; 100:n15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/57\">",
"      Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/58\">",
"      Li J, Kuruba R, Wilson A, et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One 2010; 5:e13955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/59\">",
"      Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005; 314:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/60\">",
"      Fiorucci S, Rizzo G, Antonelli E, et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005; 315:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/61\">",
"      Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/62\">",
"      Pockros PJ, Jeffers L, Afdhal N, et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007; 45:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/63\">",
"      Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/64\">",
"      Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/65\">",
"      Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/66\">",
"      Siegmund SV, Uchinami H, Osawa Y, et al. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005; 41:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/67\">",
"      Mu&ntilde;oz-Luque J, Ros J, Fern&aacute;ndez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/68\">",
"      De Minicis S, Candelaresi C, Marzioni M, et al. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. Gut 2008; 57:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/69\">",
"      Ebrahimkhani MR, Kiani S, Oakley F, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006; 55:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/70\">",
"      Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/71\">",
"      Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/72\">",
"      Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/73\">",
"      Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009; 50:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/74\">",
"      Jacobs BP, Dennehy C, Ramirez G, et al. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002; 113:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/75\">",
"      Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003; 112:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/76\">",
"      Bataller R, Sancho-Bru P, Gin&egrave;s P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/77\">",
"      Bataller R, G&auml;bele E, Schoonhoven R, et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 2003; 285:G642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/78\">",
"      Ramalho LN, Ramalho FS, Zucoloto S, et al. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 2002; 49:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/79\">",
"      Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/80\">",
"      Kurikawa N, Suga M, Kuroda S, et al. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003; 139:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/81\">",
"      Kim SY, Cho BH, Kim UH. CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation. J Biol Chem 2010; 285:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/82\">",
"      Sancho-Bru P, Bataller R, Fernandez-Varo G, et al. Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. Gastroenterology 2007; 133:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/83\">",
"      Bataller R, Sancho-Bru P, Gin&egrave;s P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005; 7:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/84\">",
"      Moreno M, Gonzalo T, Kok RJ, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010; 51:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/85\">",
"      Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/86\">",
"      George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96:12719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/87\">",
"      Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/88\">",
"      Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/89\">",
"      Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007; 292:G113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/90\">",
"      Leclercq IA, Farrell GC, Sempoux C, et al. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/91\">",
"      Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/92\">",
"      L&uuml;scher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions Suppl 1995; 45:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/93\">",
"      Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996; 98:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/94\">",
"      Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/95\">",
"      Yoshiji H, Kuriyama S, Noguchi R, et al. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 2006; 17:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/96\">",
"      Gonzalo T, Beljaars L, van de Bovenkamp M, et al. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther 2007; 321:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/97\">",
"      Tugues S, Fernandez-Varo G, Mu&ntilde;oz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/98\">",
"      Caligiuri A, Bertolani C, Guerra CT, et al. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 2008; 47:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/99\">",
"      Benedetti A, Di Sario A, Casini A, et al. Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology 2001; 120:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/100\">",
"      Hennenberg M, Trebicka J, Kohistani Z, et al. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest 2011; 91:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/101\">",
"      Wang Y, Gao J, Zhang D, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/102\">",
"      Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/103\">",
"      Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/104\">",
"      Yoshiji H, Noguchi R, Kuriyama S, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288:G907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/105\">",
"      Neef M, Ledermann M, Saegesser H, et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006; 44:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/106\">",
"      Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/107\">",
"      Tada S, Iwamoto H, Nakamuta M, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol 2001; 34:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/108\">",
"      Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004; 321:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/109\">",
"      Ogawa S, Ochi T, Shimada H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res 2010; 40:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/110\">",
"      Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008; 26:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/111\">",
"      Stefanovic, B, Schnabl, B, Brenner, DA. Inhibition of collagen a1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem 2002; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/112\">",
"      Lindquist JN, Parsons CJ, Stefanovic B, Brenner DA. Regulation of alpha1(I) collagen messenger RNA decay by interactions with alphaCP at the 3'-untranslated region. J Biol Chem 2004; 279:23822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/113\">",
"      Stefanovic B, Stefanovic L, Schnabl B, et al. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol 2004; 24:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/114\">",
"      Stefanovic L, Stephens CE, Boykin D, Stefanovic B. Inhibitory effect of dicationic diphenylfurans on production of type I collagen by human fibroblasts and activated hepatic stellate cells. Life Sci 2005; 76:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/115\">",
"      Geerts A, Rogiers V. Sho-saiko-To: the right blend of traditional Oriental medicine and liver cell biology. Hepatology 1999; 29:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/116\">",
"      Sakaida I, Matsumura Y, Akiyama S, et al. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998; 28:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/117\">",
"      Shimizu I, Ma YR, Mizobuchi Y, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/118\">",
"      Wasser S, Ho JM, Ang HK, Tan CE. Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats. J Hepatol 1998; 29:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/119\">",
"      Mann DA, Mann J. Epigenetic regulation of hepatic stellate cell activation. J Gastroenterol Hepatol 2008; 23 Suppl 1:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/120\">",
"      Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/121\">",
"      Ordov&aacute;s JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol 2010; 7:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/122\">",
"      Arthur MJ. Fibrosis and altered matrix degradation. Digestion 1998; 59:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/123\">",
"      Parsons CJ, Bradford BU, Pan CQ, et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004; 40:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/124\">",
"      Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003; 124:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/125\">",
"      Siller-L&oacute;pez F, Sandoval A, Salgado S, et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004; 126:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/126\">",
"      Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/127\">",
"      Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277:11069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/128\">",
"      Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006; 20:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/129\">",
"      Gressner AM. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/130\">",
"      Pinzani M. Unraveling the spider web of hepatic stellate cell apoptosis. Gastroenterology 2009; 136:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/131\">",
"      Iwamoto H, Sakai H, Tada S, et al. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. J Lab Clin Med 1999; 134:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/132\">",
"      Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/133\">",
"      Dekel R, Zvibel I, Brill S, et al. Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. Dig Dis Sci 2003; 48:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/134\">",
"      Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/135\">",
"      Oakley F, Meso M, Iredale JP, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005; 128:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/136\">",
"      Iwamoto H, Sakai H, Kotoh K, et al. Soluble Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic stellate cells. Dig Dis Sci 1999; 44:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/137\">",
"      Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/138\">",
"      Oakley F, Trim N, Constandinou CM, et al. Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol 2003; 163:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/139\">",
"      Fallowfield JA, Iredale JP. Targeted treatments for cirrhosis. Expert Opin Ther Targets 2004; 8:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/140\">",
"      Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/141\">",
"      Friedman SL. Targeting siRNA to arrest fibrosis. Nat Biotechnol 2008; 26:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/59/13242/abstract/142\">",
"      Issa R, Zhou X, Trim N, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003; 17:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1266 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13242=[""].join("\n");
var outline_f12_59_13242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116516461\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIBROSIS REVERSIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REMOVE INJURIOUS STIMULI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUPPRESS HEPATIC INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1924106232\">",
"      Caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malotilate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interleukin 10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMUNE MODULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NK cell stimulation/immunomodulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hepatoprotection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hepatocyte growth factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Caspase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Farnesoid X receptor ligands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DOWNREGULATE STELLATE CELL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cannabinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Silymarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Angiotensin converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cytokine-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - TGF-beta antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Endothelin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cytokine antagonism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Herbal compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1924106440\">",
"      Epigenetic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Promote matrix degradation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TIMP antagonism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Promote stellate cell apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Targeted pro-apoptotic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Increase the degradation of scar matrix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      FUTURE PROSPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116516461\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1266|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/37/36444\" title=\"table 1\">",
"      Rx for hepatic fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=related_link\">",
"      Pathogenesis of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_59_13243="MOPQRST mnemonic";
var content_f12_59_13243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    MOPQRST mnemonic for assessment of patient symptoms in palliative care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"centered\">",
"        M",
"       </td>",
"       <td>",
"        Meaning of the symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        O",
"       </td>",
"       <td>",
"        Onset of the symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        P",
"       </td>",
"       <td>",
"        Palliating and provoking factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Q",
"       </td>",
"       <td>",
"        Quality of the symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" rowspan=\"2\">",
"        R",
"       </td>",
"       <td>",
"        Related factors/symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Region and radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        S",
"       </td>",
"       <td>",
"        Severity of the symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        T",
"       </td>",
"       <td>",
"        Temporality of the symptom",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13243=[""].join("\n");
var outline_f12_59_13243=null;
var title_f12_59_13244="WHO classification malnutrition";
var content_f12_59_13244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of malnutrition according to the World Health Organization (WHO)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Moderate malnutrition",
"       </td>",
"       <td class=\"subtitle2\">",
"        Severe malnutrition (type)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetrical edema",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes (edematous malnutrition)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight-for-height",
"       </td>",
"       <td>",
"        -3 &le; SD-score &lt;-2",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         SD-score &lt;-3",
"         <sup>",
"          &Delta;",
"         </sup>",
"         (ie, more than 3 SD below the median)",
"        </p>",
"        <p>",
"         (severe wasting)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Height-for-age",
"       </td>",
"       <td>",
"        -3 &le; SD-score &lt;-2",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         SD-score &lt;-3",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         (severe stunting)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The diagnoses are not mutually exclusive.",
"     <br>",
"      &bull; This includes kwashiorkor and marasmic kwashiorkor in older classifications. However, to avoid confusion with the clinical syndrome of kwashiorkor, which includes other features, the term \"edematous malnutrition\" is preferred.",
"      <br>",
"       &Delta; Below the median NCHS/WHO reference; the SD-score (z-score) is defined as the deviation of the value for an individual from the median value of the reference population, divided by the standard deviation of the reference population.",
"       <br>",
"        SD-score = [(observed value) - (median reference value)] / [standard deviation at reference population]",
"        <br>",
"         &loz; This corresponds to marasmus (without edema) in the Wellcome clinical classification (2, 3), and to grade III malnutrition in the Gomez system (4). However, to avoid confusion, the term \"severe wasting\" is preferred.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13244=[""].join("\n");
var outline_f12_59_13244=null;
var title_f12_59_13245="Pleural effusions in HIV I";
var content_f12_59_13245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pleural effusions in HIV: Differential diagnosis and diagnostic testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Etiology",
"      </td>",
"      <td class=\"subtitle1\">",
"       History/physical exam/lab findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pleural fluid characteristics",
"      </td>",
"      <td class=\"subtitle1\">",
"       Additional tests of pleural fluid",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other helpful tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parapneumonic effusion",
"      </td>",
"      <td>",
"       Short duration of symptoms suggesting infection; parenchymal opacities on chest radiograph",
"      </td>",
"      <td>",
"       <p>",
"        Low pH",
"       </p>",
"       <p>",
"        Increased neutrophils",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Blood culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Septic embolism",
"      </td>",
"      <td>",
"       Intravenous drug abuse",
"      </td>",
"      <td>",
"       Exudative",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Blood culture",
"       </p>",
"       <p>",
"        Echocardiogram",
"       </p>",
"       <p>",
"        Chest CT may show multiple nodules",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumocystis jirovecii",
"      </td>",
"      <td>",
"       <p>",
"        Fever",
"       </p>",
"       <p>",
"        Dyspnea",
"       </p>",
"       <p>",
"        Inhaled pentamidine prophylaxis",
"       </p>",
"       <p>",
"        Low CD 4",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Small to moderate effusion",
"       </p>",
"       <p>",
"        Serous or sanguinous",
"       </p>",
"       <p>",
"        Lymphocytic",
"       </p>",
"       <p>",
"        Eosinophilic aggregates",
"       </p>",
"       <p>",
"        LDH increased",
"       </p>",
"      </td>",
"      <td>",
"       Grocott silver for P. jiroveci cysts or Diff-Quik for trophozoites",
"      </td>",
"      <td>",
"       Induced sputum or bronchoalveolar lavage for P. jiroveci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterial disease",
"      </td>",
"      <td>",
"       <p>",
"        History of exposure",
"       </p>",
"       <p>",
"        Residence in an endemic area",
"       </p>",
"       <p>",
"        Low CD4",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Lymphocytic effusion",
"       </p>",
"       <p>",
"        Adenosine deaminase &gt;50 U/L",
"       </p>",
"      </td>",
"      <td>",
"       Mycobacterial smear and culture",
"      </td>",
"      <td>",
"       <p>",
"        PPD",
"       </p>",
"       <p>",
"        Induced sputum",
"       </p>",
"       <p>",
"        Pleural biopsy for culture and identification of granulomas",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocardia",
"      </td>",
"      <td>",
"       <p>",
"        Acute or subacute onset of fever, night sweats, fatigue, anorexia, cough, dyspnea",
"       </p>",
"       <p>",
"        Low CD 4",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Modified Kinyoun acid fast stain",
"       </p>",
"       <p>",
"        PCR for Nocardia",
"       </p>",
"       <p>",
"        Maintain aerobic culture for 5 to 21 days",
"       </p>",
"      </td>",
"      <td>",
"       Blood culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryptococcus",
"      </td>",
"      <td>",
"       <p>",
"        Fever, cough, dyspnea",
"       </p>",
"       <p>",
"        CD4 &lt;100/microL",
"       </p>",
"      </td>",
"      <td>",
"       Serous exudate",
"      </td>",
"      <td>",
"       <p>",
"        Cryptococcal antigen",
"       </p>",
"       <p>",
"        Cryptococcal culture (positive in 42 percent)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Serum cryptococcal antigen",
"       </p>",
"       <p>",
"        Pleural biopsy",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histoplasma",
"      </td>",
"      <td>",
"       <p>",
"        History of residing in endemic area",
"       </p>",
"       <p>",
"        Subacute febrile illness",
"       </p>",
"      </td>",
"      <td>",
"       Serous or serosanguinous effusion",
"      </td>",
"      <td>",
"       Wright-Giemsa stain for intracellular Histoplasma yeast forms",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toxoplasma",
"      </td>",
"      <td>",
"       <p>",
"        Usually evidence of disseminated toxoplasmosis",
"       </p>",
"       <p>",
"        CD4 &lt;100 cells/microL",
"       </p>",
"      </td>",
"      <td>",
"       Unilateral or bilateral",
"      </td>",
"      <td>",
"       Giemsa stain for tachyzoites within neutrophils",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leishmaniasis",
"      </td>",
"      <td>",
"       <p>",
"        Fever",
"       </p>",
"       <p>",
"        Leukopenia",
"       </p>",
"       <p>",
"        Lymphopenia",
"       </p>",
"       <p>",
"        Thrombocytopenia",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Serologic studies positive in 50 percent",
"       </p>",
"       <p>",
"        Peripheral smear",
"       </p>",
"       <p>",
"        Bone marrow smear positive 67 percent",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13245=[""].join("\n");
var outline_f12_59_13245=null;
var title_f12_59_13246="Penis PI";
var content_f12_59_13246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the different parts of the penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13246=[""].join("\n");
var outline_f12_59_13246=null;
var title_f12_59_13247="Feminization scale";
var content_f12_59_13247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Schematic representation of grading scheme for clinical classification of androgen insensitivity syndromes (AIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 161px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Grades are numbered 1-7 in order of increasing severity (more defective masculinization). Grade 1: normal masculinization in utero; grade 2: male phenotype with mild defect in masculinization eg, isolated hypospadias; grade 3: male phenotype with severe defect in masculinization-small penis, perineoscrotal hypospadias, bifid scrotum and/or cryptorchidism; grade 4: severe genital ambiguity-clitoral-like phallus, labioscrotal folds, single perineal orifice; grade 5: female phenotype with posterior labial fusion and clitoromegaly; grade 6/7: female phenotype (grade 6 if pubic hair present in adulthood, grade 7 if no pubic hair in adulthood).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocrine Reviews 1995; 16:271. Copyright &copy; 1995 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_59_13247=[""].join("\n");
var outline_f12_59_13247=null;
          